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ABSTRACT
Health care delivery organizations bear the burden of meeting monitoring and evaluation
requirements set by numerous external organizations often at the cost of implementing internally
defined management needs. Monitoring and evaluation in global health delivery has received increasing
attention over the last few years. For instance, the World Health Organization and UNAIDS have
published guidelines and provided technical assistance for HIV/AIDS monitoring and evaluation
programs. In doing so, they establish international standards for performance measures, defining
success metrics and related data indicators. Donor organizations, such as the President's Emergency
Plan For AIDS Relief (PEPFAR), the Global Fund to Fight AIDS, Tuberculosk and Malaria (GFATM), and
the World Bank's Multi-Country AIDS Program (MAP), have also contributed to defining HIV/AIDS
success measures and data indicators in the way that they require funding recipients to report on
performance. The multitude of players at the global level has made monitoring and evaluation in
HIV/AIDS management confusing with regards to coordination, priority-setting, authority, and
information clarification.
Health care delivery organizations that act as local service providers must balance fulfilling
donor requirements with addressing internal management priorities, which considers beneficiary needs,
internal strategy, and available resources. This thesis discusses the challenge of obtaining this balance by
comparing data indicators set at the global level with data monitoring priorities at the enterprise level.
A case study of Kyetume Community Based Health Care Programme, a health care delivery organization
in Mukono, Uganda, is presented to illustrate management complexity of data monitoring at the
enterprise level. The application of basic data management solutions at a local service provider shows
how business management practices can be applied towards improving health care delivery processes.
Drawing upon the case study as well as the concepts presented about global and enterprise level
contributions to monitoring and evaluation, this paper discusses stakeholder incentives and the
implications on monitoring HIV/AIDS care delivery.
Thesis Supervisor: Anjali Sastry
Title: Senior Lecturer in System Dynamics, MIT Sloan School of Management
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Chapter 1 : Introduction
Despite years of foreign aid and assistance, the HIV/AIDS epidemic in sub-Saharan
Africa remains a challenge that lacks a sustainable solution. The last three decades have seen
countless initiatives to reduce the burden of HIV/AIDS through scientific research and health
care delivery in the form of efforts involving academia, international agencies, NGOs, and
governments designed to tackle AIDS. Regulatory measures and institutional innovations, such
as the World Trade Organization's Doha Declaration on TRIPS and Public Health' as well as
public-private partnerships like the International AIDS Vaccine Initiative (IAVI)2, have
decreased the price of drugs, increased access to treatment, and accelerated AIDS research.
Today, there are 33.3 million people living with HIV. Of the 15 million HIV positive people
who live in low- and middle- income countries, 5.2 million people have access to necessary
drugs (UNAIDS, 2010). In addition, new challenges have arisen as a consequence of the
multitude of players in the fight against AIDS.
The following diagram shows that while the number of people living with HIV is still
increasing, the rate of that growth is slowing down. Related to this is the decreasing number of
people newly infected with HIV and the increase of AIDS deaths worldwide. These trends
suggest that efforts towards reducing the spread of HIV have seen some success, though the
overall epidemic is still significant and growing.
WTO's Doha Declaration on TRIPS and Public Health increased access to essential medicines
by reaffirming member states' rights to circumvent drug patents to protect public health.
2 The International AIDS Vaccine Initiative, known as IAVI, is a not-for-profit public-private
partnership that researches and develops potential HIV vaccines. Contributing donors include
national governments as well as private foundations and individuals.
Figure 1. Number of People Living With HIV, Number of People Newly Infected with HIV, and
Number of AIDS deaths in the world, 1990-2008
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Source: WHO, HIV/AIDS Program Highlights 2008-09 (WHO, May 2010)
In spite of the common goal to reduce the burden of AIDS, demands made by the parties
that hold resources have often, inadvertently, hindered innovation of the organizations that they
fund. In particular, by adding contingencies to needed capital, donors consequently dictate the
actions taken by health delivery organizations and government groups. This paper focuses on
data monitoring within an HIV/AIDS health care delivery organization. Specifically, the paper
aims to address the struggle between a health care delivery organization's internal strategy and
requirements set by external parties, particularly those of donor organizations. In doing so, I will
examine the current framework for defining, attaining, and measuring success for an HIV/AIDS
health care delivery program.
1.1 Monitoring and Evaluation - Focus on Monitoring
Monitoring and evaluation in health care delivery organizations has been receiving
increasing attention in the last decade. In January 2007, WHO Director-General Dr. Margaret
Chan stated in her inaugural address, "What gets measured gets done" (Chan, 2007). This
sentiment is not new, but it is relevant to the status of public health today. Global health and
management experts recognize the need to collect and analyze data, but the details regarding
what to collect and how the information can be used are less concrete at this point in time. Still,
global health players such as the WHO and UNAIDS have taken great strides in starting the
conversation and establishing global standards for HIV/AIDS monitoring and evaluation, which
will be further explored in the following chapter.
The World Bank defines monitoring and evaluation as follows. Monitoring is "a
continuing function that uses systematic collection of data on specified indicators to provide
management and the main stakeholders of an ongoing development intervention with indications
of the extent of progress and achievement of objectives and progress in the use of allocated
funds" (World Bank, 2011). Monitoring provides regular tracking of inputs, activities, outputs,
outcomes and impacts. Benefits of monitoring for management purposes include structured and
data-driven measurement of program activities. The limitation of monitoring is that it covers
only certain dimensions of a project's or program's activities, where each indicator measures one
isolated aspect at a time.
Evaluation, on the other hand, is defined as "the process of determining the worth or
significance of a development activity, policy or program.. .to determine the relevance of
objectives, the efficacy of design and implementation, the efficiency or resource use, and the
sustainability of results" (World Bank, 2011). Lessons learned from evaluation can be
incorporated into the decision-making processes at the enterprise, donor, government, and
international levels. Moreover, evaluation provides a more balanced interpretation of
performance relative to monitoring indicators. However, conducting evaluations are time-
consuming and costly. Therefore, evaluations are done less frequently than monitoring.
The following table from Family Health International (FHI) provides examples of
monitoring versus evaluation for HIV/AIDS programs. Monitoring focuses on inputs, process,
and outputs, whereas evaluation focuses on outcome and impact. However, monitoring and
evaluation overlap in that they both consider outcomes, though from different angles.
Figure 2. HIV/AIDS Monitoring Versus Evaluation
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Source: WHO, A Guide to Monitoring and Evaluating IIV/AIDS Care and Support (WHO,
March 2004)
Evaluation requires in depth analysis of actions, strategies, and policies of an
organization. It requires the involvement of management, community stakeholders, supervisors,
and donors to compare performance against goals, focusing on impact and the organization' s
model of change. While evaluation is extremely important in measuring performance of an
organization, the focus of this paper will be on monitoring. Monitoring tends to focus more on
the output and outcome aspects of implemented activities, requiring regular data tracking that is
part of daily activities in an organization. Monitoring provides opportunity for the early
detection of problems so that corrective action can be taken. It also creates a foundation from
which an organization can measure progress towards its goals (UNFPA, Aug 2004).
1.2 Application of M&E
The design of a national monitoring and evaluation system for HIV can be guided by an
international standard such as the following approach, which appears in documents published by
the Global Fund and UNAIDS. The framework looks at M&E from the lens of answering public
health questions. The logic behind M&E begins with the identification of a problem, followed by
an analysis of contributing factors and the interventions and inputs needed. Monitoring and
evaluation is introduced to assess the efficacy of the interventions by looking at process
measures and how well the interventions are implemented. Outcome measurement looks at the
difference achieved by the interventions. Further impact studies survey the scale and influence
on the epidemic at large (World Bank, 2004).
Figure 3. A Public Health Questions Approach to M&E in HIV
Fig. 1. A public health questions approach to M&E in HIV
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UNAIDS, Organizing Framework for a Functional National HIV Monitoring and Evaluation
System (UNAIDS, April 2008). GFATM, Monitoring and Evaluation Toolkit (The Global Fund
to Fight AIDS, Tuberculosis, and Malaria, Feb 2009).
Using this framework, national level indicators can be extracted to evaluate the state of
the HIV epidemic and the performance of initiatives that have been meant to fight HIV within
the country. Ideally, the local health care delivery organization's purpose and strategy should
align with the national strategy.
Standard M&E classification defines output, outcome, and impact as follows. Output is
defined as the result of program activities. It relate to the direct products or deliverables of
program activities, such as number of counseling sessions completed, number of people reached,
and number of materials distributed. Outcome is the effect of program activities on target
audiences or populations, such as change in knowledge, beliefs, skills, behaviors, access to
services, and environmental conditions. Impact is defined to be the longer-range, cumulative
effect of programs over time such as change in HIV infection, morbidity, and mortality; impacts
are rarely, if ever, ambiguously attributable to a single program, but a program may, with other
programs, contribute to impacts on a defined population (PEPFAR, Aug 2009). The following
table from FHI gives some examples of outcomes versus impacts for an HIV/AIDS program.
Figure 4. Potential Program Outcome/impact Measures
Program Outcome Program Impact
(short-term and intermediate effects) (long-term effects)
+ changes in HIV/AIDS-related attitudes 
- sustained changes in HIV/STI-related risk behaviors
* HIV/ST-related risk behaviors * trends in HIV/AIDS rates
* trends in STI rates (e.g., gonorrhea) 
- AIDS-related mortality rates
* increase in social support/community response 
- reduced individual and societal vulnerability
to HIV/AIDS
- sustained changes in societal norms
Source: Family Health International, Evaluating Program for HIV/AIDS Prevention and Care in
Developing Countries: A Handbook for Program Managers and Decision Makers (Family Health
International, 2006)
Ideally, the logic of defining indicators for local service providers should be similar to
that of the national level framework, beginning with the identification of the problem to be
solved. After considering contributing factors and brainstorming possible solutions, an
organization decides on what aspect of the problem they should address and what activities they
can realistically pursue. Baseline data is gathered, targets are set, and indicators are designed
based on measuring progress towards those objectives. With well-defined indicators, managers
can set realistic targets, measure progress, compare performance, identify problems early on, and
articulate improvements and achievements over time.
M&E can be useful for multiple purposes in an individual health care delivery
organization. In the area of strategic decision-making, M&E can inform policy, operations, and
strategy for extension, expansion, or replication. It can help identify strategies and activities that
are successful or unsuccessful. For operation management, M&E is useful to improve program
quality and to demonstrate accountability to decision makers. In terms of stakeholder
management, M&E is used to justify and validate the necessity of programs to donors and
partners. When stakeholders are involved in decision-making, they are able to participate in
decisions that determine program output and quality. Finally, M&E plays an important role in
organizational learning and impact. Regular internal data monitoring and evaluation measures
the effectiveness of programs and projects. With quantitative and qualitative data analysis, an
organization can identify the things that do or don't work and why. Building on this type of
knowledge can lead to an articulation of best practices and validation of competencies and
achievements.
Unfortunately, the process of problem solving and data monitoring for HIV/AIDS health
care delivery has been complicated by misaligned incentives, a lack of coordination among the
multitude of stakeholders, resource limitations, and a need for bottom up participation in
decision making from enterprise level management. Even upstream, at national and international
levels, the number of stakeholders and decision-makers has over-complicated the setting of
priorities. The following diagram of Kenya's M&E data flow illustrates the complexity of a
national HIV/AIDS M&E program.
Figure 5. Organization of Flow of M&E Data in Kenya
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Ministry of Planning and National Development; NACC: National AIDS Control Council; NASCOP:
National AIDS and STI Control Programme; NGO: Non-governmental organisation; PARTO Provincial
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Information Officer; PMO: Provincial Medical Officer.
Source: UNAIDS MERG, Guidance on Capacity Building for HIV Monitoring and Evaluation
(UNAIDS, Jan 2010)
1.3 Key Issues and Structure
This paper strives to address four key issues. First, the multitude of players in HIV/AIDS
management creates an environment of confusion regarding priority-setting, authority, and
information clarification. Second, health care delivery organizations face difficulties to balance
stakeholders because disconnected priorities from donors, beneficiaries, and internal
management create an incentive structure with contradictions. Third, resource constraints in
developing areas make fulfilling donor requirements impossible or impractical. And, finally, the
relative weakness of local service providers' abilities to innovate and improve internal M&E is
an issue that needs to be remedied.
The purpose of this paper is to understand the roles of major stakeholders in HIV/AIDS
care and how their interactions contribute to M&E design and activities. I will focus on the
design and construction of data monitoring processes at the enterprise level, comparing an ideal
logical flow to practices in reality. In order to understand the M&E experience of a local care
delivery organization, I will present a case study to provide a glimpse of reality on the ground.
Analysis of the different stakeholder's roles motivate conclusions regarding HIV/AIDS M&E
challenges and actions that can be taken to overcome those challenges.
The following sections introduce the major stakeholders in monitoring and evaluation of
HIV/AIDS programs. The first section considers the global level, for which I will examine
international organizations that fund or establish guidelines for HIV/AIDS programs. The
selected donor organizations that are presented in the chapter are the three largest financiers of
HIV/AIDS programs in the developing world: The United States President's Emergency Plan
For AIDS Relief (PEPFAR), The Global Fund to Fight AIDS, Tuberculosis, and Malaria
(GFATM), and The World Bank's Multi-Country HIV/AIDS Program for Africa (MAP) (Center
for Global Development, Oct 2007).
It is important to note that these donors often provide funding on a national level, where
M&E indicators are designed with regard to national levels. Enterprise level HIV/AIDS
programs may receive funding indirectly from these large pools of funds. For instance, the
Country Coordinating Mechanism, the structure through which the Global Fund communicates
with in each country, can choose a non-governmental primary recipient for GFATM resources
(The Global Fund to Fight AIDS, Tuberculosis, and Malaria, 2011). PEPFAR can fund umbrella
organizations that reach out to smaller civil society organizations with HIV/AIDS programs (The
US President's Emergency Plan For AIDS Relief, 2011). The World Bank tends to communicate
only at the national government level. However, governments may distribute MAP resources to
chosen local service providers that fit within the national and international agenda (World Bank,
2011). By comparing their measures for successful performance with those of a health delivery
organization, we can see how indicators that are defined at a high level trickle down to the
management of an individual health care delivery organization. Moreover, the degree of
influence that these three large organizations have in decision-making processes for worldwide
HIV/AIDS initiatives is worthy of closer analysis.
In addition to these three donor organizations, I will also present M&E guidelines and
tools published by the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the World
Health Organization (WHO). Although these two international organizations do not participate
directly in funding, they are heavily involved with global health coordination and setting
3
standards for recommended practices .
The subsequent section focuses on data monitoring from the perspective of the health
care delivery organization at the local level. The M&E priorities are different at this level
depending on what aspect of HIV/AIDS care that the organization chooses to address and the
strategies and activities carried out, which are often tailored to unique contextual factors. In this
regard, the local health care delivery organization is intimately tied to the patient population
served, whose needs are considered in the organization's strategy and model. The section will
3 Exception: In 2003, UNAIDS and WHO launched the 3 x 5 Initiative, which aimed to provide
three million people living with HIV in low- and middle income countries with antiretroviral
treatment (ART) by 2005.
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use the care delivery value chain framework to approach strategy in global health delivery
management. Through this tool, I hope to provide lenses through which the problem of data
management can be analyzed.
Finally, a real world example of data monitoring challenges is presented in a case study
of Kyetume Community Based Health Care Programme (KCBHCP), a health care delivery
organization located in rural Mukono, Uganda. Though it is impossible to present all issues
faced by unique health care organizations, KCBHCP's experience with data monitoring provides
insights into some of the challenges and achievements made at the local service provider level.
1.4 Methodology
This paper draws upon information from three types of sources. The first type of
information is written and publicly available. This includes articles, papers, books, and
information that is posted online through the websites of WHO, UNAIDS, World Bank,
PEPFAR, and GFATM. As a student without an extensive background in global health, I take
the perspective of an external researcher, making use of publicly available information as
opposed to an insider, who may know the ins and outs of the field from unpublished sources.
The second type of information from which this paper draws upon is interviews with experts in
the field. Insights collected from academic researchers, managers at NGOs, and M&E experts
have provided a range of perspectives that reflect current HIV/AIDS data monitoring practices.
The third source of data comes from the experience of a team of students who visited Kyetume
Community Based Health Care Programme (KCBHCP) through MIT's Global Health Delivery
Lab, an action-learning course offered at the Sloan School of Management. As a member of this
team, I assisted in developing tools to improve data monitoring at KCBHCP. With the help and
participation of the KCBHCP staff, I draw upon information attained at KCBHCP to inform the
section describing local service provider perspectives.
Chapter 2 : Global Level - International Standards and Donor
Requirements
Analysis of the three largest sources of funding for HIV/AIDS initiatives in developing
countries can shed light on the current status of M&E practices. The donors presented in this
chapter are the U.S. Presidents' Emergency Plan to For AIDS Relief (PEPFAR), the Global Fund
for AIDS Tuberculosis and Malaria (GFATM), and the World Bank's Multi-Country HIV/AIDS
Program for Africa (MAP). Additionally, Joint United Nations Programme on HIV/AIDS
(UNAIDS) and the World Health Organization (WHO) are presented because of their significant
influence in communicating and shaping international standards for HIV/AIDS monitoring. The
analysis will focus on each organization's contribution to the fight against HIV/AIDS, the
relationship with its recipient or target audience, and the recommended or required M&E
guidelines and policies.
2.1 PEPFAR
Since President George W. Bush started the fund in 2003, PEPFAR has committed $32
billion to bilateral HIV/AIDS programs, the Global Fund, and bilateral TB programs. For 2011,
President Obama requests $7 billion, including $5.74 billion for bilateral HIV/AIDS programs,
and $1 billion for the Global Fund. PEPFAR partners directly with 30 countries, providing
support for 11 million people, of which 3.8 million are orphans and vulnerable children
(PEPFAR, 2010).
PEPFAR funding is allocated towards treatment and care for patients as well as for
orphans and vulnerable children. Recipient organizations tend to be international NGOs, most of
which are American. The money is then disbursed to local care delivery organizations under the
requirements and targets set by the primary recipient organization. Reporting requirements are
stringently determined by PEPFAR, which places priorities on achieving targets (Center for
Global Development, Oct 2007). In this sense, funding is not flexible in allowing recipients to
prioritize their own programs' activities. PEPFAR recipients, therefore, are not given the
freedom to design their programs to be locally specific.
In 2009, PEPFAR published a document called Next Generation Indicator Reference
Guide that details the list of indicators that PEPFAR funded programs are requested to track. A
full list of these indicators is attached in Appendix A. The indicators are categorized by type of
intervention (i.e. prevention, care, treatment), source of data collection, national or programmatic
level, and whether or not it describes output, outcome, or impact (PEPFAR, Aug 2009).
Though the list is quite long and thorough, only a chosen few are used often in
publications to represent PEPFAR program results. Based on publicly available materials and
program reports, PEPFAR selects the following types of indicators to report on program results:
the number of people supported with ART, the number of PLWHA 4 supported with care, the
number of orphans and vulnerable children supported, the number of HIV positive pregnant
women on prophylaxis, the number of HIV negatives babies born to HIV positive mothers as a
result of PEPFAR's PMTCT5 efforts, and the number of people that PEPFAR has supported to
obtain counseling and testing (PEPFAR, 2010). Appendix B gives PEPFAR's program results
for Uganda, providing an example of selected indicators to represent performance. Up until
September 2009, PEPFAR kept record of the number of people supported indirectly from
PEPFAR funding. This number is a projection of the number of people benefitting from systems
strengthening and capacity building of the national HIV/AIDS program that the US government
contributed to. However, starting from 2010, PEPFAR will instead report on national
achievements in service delivery and health systems strengthening as described in the Next
Generation Indicators Reference Guide (PEPFAR, Aug 2009).
The detail with which PEPFAR describes and categorizes indicators suggests depth of
research and continuous update of performance measures. The documents are available online,
and are easily accessible. PEPFAR's large presence in developing countries indicates its
substantial contribution to HIV/AIDS health care delivery.
2.2 The Global Fund
The Global Fund to Fight AIDS, Tuberculosis, and Malaria was formed in 2002 and has
become the dominant financier for worldwide efforts against the three disease areas. To date, the
Global Fund has committed $21.7 billion in 150 countries (The Global Fund to Fight AIDS,
Tuberculosis, and Malaria, 2011). The United States is the largest donor of the Global Fund
having pledged $4 billion between 2011 and 2013, partially through PEPFAR (PEPFAR, 2010).
For an international fund of its size, the Global Fund has earned respect for its attempt to be
4 "PLWHA" is an acronym for people living with HIV/AIDS.
5 "PMTCT" is an acronym for prevention of mother-to-child transmission.
transparent about its members, its activities, and the grants that are both accepted and rejected.
Some of the indicators that the Global Fund chooses to represent its work include the number of
programs funded and the number of lives saved. The Global Fund has provided publicly
available guides on its website for performance evaluation as well as posted success stories to
demonstrate lives saved as a result of Global Fund efforts. Disbursement is managed through a
Country Coordinating Mechanism (CCM), where primary recipients are usually government
entities. However, recipients can also be NGOs that are specified by the CCM (The Global Fund
to Fight AIDS, Tuberculosis, and Malaria, 2011). The Global Fund, therefore, works both with
government and non-government recipients.
The Global Fund uses a performance based operating model called "Raise It, Invest It,
Prove It" that is also shared by the GAVI Alliance (The Global Fund to Fight AIDS,
Tuberculosis, and Malaria, Nov 2009). With an intention to listen closely to local needs and to
foster ownership of project monitoring, the Global Fund requires the host program to specify
pre-determined M&E indicators in the grant proposal. Requiring the formation of a CCM, which
must involve public and private sectors, including governments, multilateral or bilateral
agencies, non-governmental organizations, academic institutions, private businesses and people
living with the diseases, suggests that the Global Fund places a great deal of burden on the
recipient (The Global Fund to Fight AIDS, Tuberculosis, and Malaria, 2011). However, the
CCM is necessary for the Global Fund to maintain a consistent relationship with its recipient
countries, ensuring the involvement of multiple stakeholders in its decision-making processes.
The requirements on defining indicators and data capturing also reflect the Global Fund's
objective to increase the grant recipients' participation and ownership of the monitoring aspect of
the project. In this sense, the Global Fund allows more flexibility for its recipients to design and
prioritize the activities in each program. Although M&E indicators ultimately need to be
approved by the Global Fund, the process is more of a negotiation than with PEPFAR. The
Global Fund, in collaboration with UNAIDS, WHO, World Bank, UNICEF 6, and USAID 7,
published a Monitoring and Evaluation Toolkit in 2009 that describes many of the internationally
6 UNICEF is the United Nations Children's Fund that provides humanitarian and developmental
assistance to children and mothers in developing countries.
7 USAID is the United States Agency for International Development is an independent federal
government agency that provides economic, developmental, and humanitarian assistance in
support of the foreign policy goals of the United States.
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accepted concepts for effective M&E. For HIV specifically, the toolkit gives examples of output
indicators that can be used for specific service delivery areas, such as behavior change
communication or counseling and testing (The Global Fund to Fight AIDS, Tuberculosis, and
Malaria, Feb 2009).
The top indicators for routine Global Fund reporting for HIV/AIDS programs include: the
number of people with advanced HIV infection who are currently receiving ART8, the number of
adults who received in HIV test in the last year and know their results, the number of HIV
positive pregnant women who receive ARVs to prevent mother-to-child transmission, the
number of condoms distributed, the number of people benefitting from community based
programs such as support for orphan and vulnerable children as well as behavior change
communication and prevention outreach activities, the number of TB registered patients who
received an HIV test, and the number of people trained. The top indicators for outcome and
impact assessment for HIV/AIDS programs include: the percentage of young adults who are HIV
positive, the percentage of people who started ART that are still on treatment after a year, the
percentage of HIV negative infants born to HIV positive mothers, the percentage of adults who
have multiple partners that used a condom during their last sexual intercourse, and the mortality
rate of children under age five (The Global Fund to Fight AIDS, Tuberculosis, and Malaria,
2010). Appendix C lists the Global Fund Top Ten Indicators. The Global Fund indicators reflect
those reported on by WHO, UNGASS 9, and UNAIDS.
The Global Fund attempts to standardize communication, grant disbursement, and M&E
processes by requiring the establishment of CCMs. Simultaneously, a great deal of
customization and negotiation occurs in the grant proposal process, where the potential recipient
determines indicators for performance monitoring. In this way, indicators can be tailored
appropriately to specific situations.
8 "ART" is an acronym for antiretroviral therapy. There are several classes of antiretroviral
drugs (ARV) that can be taken through fixed-dose combination pills or personalized by a doctor.
9 UNGASS is the United Nations General Assembly Special Session on HIV/AIDS through
which ministers from 189 countries came together to address the global emergency of the
HIV/AIDS epidemic. UNGASS collaborates frequently with UNAIDS, especially in the
communication of core indicators. UNGASS. (March 2009). UNGASS Guidelines on
Construction of Core Indicatorsfor 2010 Reporting.
2.3 The World Bank: MAP
The World Bank's Multi-Country HIV/AIDS Program for Africa has provided $2 billion
to 35 countries since its inception in 1999 (World Bank, 2011). More so than PEPFAR and the
Global Fund, MAP deals specifically at the national government level, working to promote
countrywide improvement from top down rather than from ground up. The program was
designed to have three stages of development. The first stage is to establish essential
infrastructure of care delivery, including enacting policy, engaging community members,
learning from trial, and increasing capacity. The second stage is to scale up prevention,
treatment, and care. The third stage is to focus on areas and groups in which HIV continues to
spread. In 2007, the World Bank published its Agenda for Action 2007-2011, with the intention
to reach Millennium Development Goal Six, to halt and reverse the spread of HIV/AIDS. The
Agenda for Action rested on four strategic pillars (World Bank, March 2008).
Figure 6. Pillars ofAction in the World Bank's Agenda for Action
Pillar 1 Focus the response through evidence-based and prioritized
HIV/AIDS strategies, integrated into national development planning.
Pillar 2 Scale up targeted multisectoral and civil society responses.
Pillar 3 Deliver more effective results through increased country M&E
capacity.
Pillar 4 Improve donor harmonization and coordination.
Source: World Bank, The World Bank's Commitment to HIV/AIDS in Africa: Our Agenda for
Action 2007-2011 (World Bank, March 2008)
These pillars of action reflect the World Bank's understanding that an appropriate
response in one location and circumstance is not necessarily appropriate in another. HIV/AIDS
programs and strategies must be tailored to specific country epidemics though there is benefit in
sharing successful practices and learnings across programs. Pillar 2 highlights the need for
health systems strengthening and the need to integrate all players within a national system to be
cohesive, supportive, and effective. Pillar 3 calls for the development and operationalization of
M&E systems at the country level. To this end, the World Bank suggests the adoption of the
HIV/AIDS Results Scorecard (see Appendix D) and the assistance of GAMET10. Pillar 4
recognizes the lack of harmonization among donors that hinder scale up of national HIV/AIDS
programs. Though the motivation exists to align international aid institutions, the World Bank's
reduction of stress on human capacity and supply chain constraints is difficult to quantify.
For the purpose of understanding the World Bank's perspective on monitoring
HIV/AIDS as well as the actions that have been taken towards M&E, a closer look at GAMET
and the HIV/AIDS Results Scorecard is of interest. GAMET works closely with UNAIDS to
help national governments develop and implement M&E frameworks. In 2007, GAMET
published a handbook for planning and managing HIV/AIDS results in which it describes how to
use a logical framework to establish a program that is evidence based and oriented towards
results (Center for Global Development, Oct 2007). Additionally, guidelines and tools that
inform M&E development have been published by the World Bank and UNAIDS in such
documents as the Monitoring and Evaluation Operations Manual for National AIDS Councils
(UNAIDS, World Bank, Aug 2002).
The World Bank's Africa Region, in collaboration with GAMET, developed the
HIV/AIDS Results Scorecard. The scorecard is based on indicators agreed upon by I JNGASS
the Millenium Development Goals, and the World Bank's International Development
Association. It also accounts for the OECD's Paris Declaration on harmonization and
minimizing data requirements. Indicators were selected with consideration of country reporting
capacity, availability of baseline data, and alignment with reporting requirements of UNAIDS,
GFATM, and PEPFAR (World Bank, 2007). The scorecard indicators are categorized into six
parts: demographics, challenges, final outcomes, intermediate outcomes, financial commitments,
and disbursements. Some of the highlighted national indicators from the scorecard include:
number of people living with HIV, percentage of adults with multiple partners that report
condom use, the number of HIV positive pregnant women who receive prophylaxis, the number
of civil society organizations (CSOs) supported for subprojects, the percentage of national AIDS
10 GAMET, or the Global AIDS Monitoring and Evaluation Team, is a World Bank organization
with the mission to improve the quality of HIV/AIDS monitoring and evaluation and build
national capacity to support its own M&E system. World Bank. (n.d.). Global Monitoring and
Evaluation Team. Retrieved from
http://web.worldbank.org/WBSITE/EXTERNAL/TOPICS/EXTHEALTHNUTRITIONANDPO
PULATION/EXTHIVAIDS/0,,contentMDK:215149 10~pagePK:210058~piPK:210062~theSiteP
K:376471 ,00.html
authorities that report and disseminate data from the HIV M&E framework, and the estimated
investment required to reach HIV/AIDS goals (World Bank, 2007). Many of the Challenge and
Outcome indicators, which are sections B, C, and D on the scorecard, echo those seen in
PEPFAR's set of indicators (see Appendix D). Challenge indicators include number of people
living with HIV, which is found in the UNAIDS report as well. Outcome indicators include
statistics on condom use, which are found in UNGASS core indicators as well as PEPFAR and
MAP indicators. Other HIV/AIDS Scorecard indicators focus on national financial needs, which
falls more in the scope of World Bank priorities. Though the World Bank interacts with national
governments rather than CSOs, the determination of the national AIDS agenda and resource
allocation affect enterprise level health delivery organizations.
2.4 UNAIDS
WHO and UNAIDS, despite not being financiers, are key players in providing technical
assistance and determining guidelines for HIV/AIDS programs. They are also recognized as
global authorities in compiling country level reports and disseminating information. For the
purpose of setting international standards of success, WHO and UNAIDS are globally important
in influencing governance and contributing to decisions made by donors, national health
authorities, as well as health delivery organizations. Therefore, the recommendations suggested
by WHO and UNAIDS carry weight in the determination of performance measures on national
and subnational levels.
In 1998, the UNAIDS Monitoring and Evaluation Reference Group (MERG) was
created to bring together donors, NGOs, and technical experts to strengthen M&E within
UNAIDS and set international standards for national indicators, global M&E guidelines, and
tools that can be used at the country level for AIDS programs. Among the many partners of
UNAIDS MERG are PEPFAR, the Global Fund, and the World Bank. By pre-assessing
indicators, MERG intends to promote harmonization of indicators and reduce reporting burden.
The process by which the MERG Indicator Review Panel chooses indicators is described in the
following diagram (UNAIDS, Jan 2010).
Figure 7. New Indicator Review Process
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Source: UNAIDS, Indicator Standards: Operational Guidelines for Selecting Indicators for the
HIV Response (UNAIDS, Jan 2010)
The Indicator Assessment Tool uses six standards to screen that the new indicator: is
needed and useful, has technical merit, is fully defined, is feasible to collect and analyze, has
been field tested or used in practice, and is balanced and coherent (UNAIDS, Jan 2010). MERG
makes such tools available through publications so that donor organizations, NGOs, and national
governments can synchronize a common set of indicators to use. For instance, WHO and the
Global Fund have both made use of the Indicator Assessment Tool. The extent to which
MERG's work benefits service organizations at the local level is less certain. The topic of
streamlining reporting processes will be discussed further in the following chapter.
The UNAIDS Report on the Global AIDS Epidemic, accepted as an authority for the
world's HIV/AIDS data, used a set of indicators that were developed as a complement to the
indicators specified by the United Nations General Assembly Special Session on HIV/AIDS
(UNGASS, March 2009). The list of UNGASS's 25 core indicators to measure national
performance and progress in the fight against AIDS are attached as Appendix E.
2.5 World Health Organization
Chapter 2, Article 2 of the WHO constitution states (WHO, July 1946):
"In order to achieve its objective, the functions of the Organization shall be: (a) to act as
the directing and coordinating authority on international health work; (b) to establish
and maintain effective collaboration with the UN, specialized agencies, government
health administrations, professional groups and such organizations as may be deemed
appropriate; (c) to assist Governments, upon request, in strengthening health services;
(d) to furnish appropriate technical assistance... upon the request or acceptance of
Governments...."
These first listed functions of the WHO have very important implications for global health
governance. First, it is written as a constitutional mandate for the WHO to be the coordinating
authority of international health work. This is an extremely important role considering the
multitude of players on the global health stage. Yet, the extent that the WHO has been successful
in this task is arguable. The authority of the WHO is given voluntarily by member-states, all of
which clearly hold their own countries at priority. However, if the authority and legitimacy can
be granted, the WHO fills a very necessary position in standardizing guidelines, data indicators,
and establishing international best practices. Additionally, governments turn to WHO for
technical assistance, which includes helping countries to generate quality data, monitor progress
against relevant indicators, and use data to improve health-sector response to HIV (WHO, May
2010).
Furthermore, in her inaugural address, WHO Director-General Dr. Margaret Chan made
the following statements (Chan, 2007): "I believe it is also our job to constantly assess the
impact of our activities... Good performance - action with an impact - requires clear and
cohesive guidance from WHO...the true measure of our effectiveness rests with our impact on
people - people within countries." Dr. Chan's speech emphasized the WHO's constitutional
mandate as the coordinating body for global health and the WHO's role to measure performance
by impact of activities on the people.
Keeping true to this objective, WHO publishes global health reports that demonstrate
continual monitoring of epidemics and impact of activities promoted by the WHO. The
following diagram presents one such monitoring indicator from a 2010 publication regarding the
WHO's HIV/AIDS Program during 2008-09 (WHO, May 2010). The graph shows where we are
relative to the 80% goal set by UNGASS for the percentage of pregnant women living with HIV
receiving ARVs for PMTCT. By presenting this type of data in its program publication, WHO
illustrates that the organization defines a success measure by percent coverage of ARVs for
pregnant women living with HIV, that a target has been set, and that data is collected regularly to
monitor the progress towards the indicated goal.
Figure 8. Percentage ofpregnant women living with HIV receiving AR Vs to prevent mother-to-
child transmission of HIV in 20 high-burden countries, 2008
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Source: WHO, HIV/AIDS Programme Highlights 2008-09 (WHO, May 2010)
In addition to delivering statistics and reports on its activities, WHO publishes
monitoring and evaluation guidelines that are widely accepted by national governments as well
as local health care providers. Every year, WHO collaborates with UNAIDS and UNICEF to
deliver Towards Universal Access, which is a report and a reference for health sector progress
for HIV. However, WHO provides recommendations and guiding frameworks for HIV/AIDS
efforts on all three levels: global, national, and local. In collaboration with UNAIDS, UNICEF,
FHI, and USAID, WHO also published a Guide to Monitoring and Evaluating HIV/AIDS Care
and Support, in which care and support programs are defined, and indicators for M&E are
suggested (WHO, March 2004). Roles for activities and M&E at each level are described in the
document as follows.
Figure 9. Monitoring and Evaluation Roles and Activities at Program, National, and Global
Levels
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The diagram indicates that coordination at the different levels (global, national, facility)
should result in the creation of a supportive regulatory environment and a developed
infrastructure from the global and national levels, such that facilities can take care of program
activities that bring real impact in the fight against HIV/AIDS. Furthermore, coordination in
policy, strategy, and guidelines across these levels should lead to more effective delivery (WHO,
March 2004). In addition to looking at responsibilities at the global, national, and local levels,
WHO describes the many facets of HIV/AIDS care and support that must be addressed to
provide complete care. The following diagram describes the different aspects of HIV/AIDS care
and support that must be accounted for within a comprehensive system.
Figure 10. Four Main Domains of Hi V/AIDS Comprehensive Care
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Source: WHO, National AIDS Programmes: A Guide to Monitoring and Evaluating HIV/AIDS
Care and Support (WHO, March 2004)
Though the responsible party is not listed, this type of care is generally delivered at the
local service provider level, which, in turn, must be supported by higher district and national
players in order to provide effective and quality services. A list of WHO recommended
HIV/AIDS care and support program indicators for monitoring and evaluation are attached in
Appendix F.
From interviews with experts in the field, I learned that WHO guidelines are followed at
the service provider level as well as national and state level. Matthew Peckarsky, the Health
Surveillance and Evaluation Manager at Partners in Health", indicated that Partners in Health
follows WHO guidelines and indicators to design the organization's M&E (Peckarsky, 2011). In
my conversations with Veronica Miller, Executive Director of the Forum for Collaborative HIV
Research' 2 (Miller, 2011), and Pamela Ogata of the Los Angeles Office of AIDS Program and
Policy'3 (Ogata, 2011), WHO guidelines were brought up on multiple occasions as a source of
reference for informing M&E program design and implementation.
2.6 Collaboration Among the Global Players
These five important players listed here collaborate with one another on many
occasions. The documents published by each organization often cite the other four as partners
and references. However, the documents themselves are not the same on each website. As seen
by comparing recommended indicators, many of donor requirements and international guidelines
share similar ideas and the same monitoring data components. Yet, the process of setting up an
M&E system and the relationships between the donor organization/international agency and the
service provider/national government vary tremendously, meaning that working with more than
one of the five will require setting up multiple reporting systems. Though it is encouraging to
see that WHO, UNAIDS, PEPFAR, GFATM, and MAP communicate with one another on some
levels and that they all aim to improve existing M&E, the result of these collaborations clearly
needs some improvement.
" Partners in Health (PIH) is a non-profit health care organization based in Boston that provides
health care for the poor. The PIH model is based on five principles: access to primary health
care, free health care and education for the poor, community partnerships, addressing basic social
and economic needs, and serving the poor through the public sector.
1 The Forum for Collaborative HIV Research is a public-private partnership at the University of
California, Berkeley Washington Campus.
" The Office of AIDS Programs and Policy (OAPP) is a program office of the County of Los
Angeles Department of Public Health. It directs the overall response to the HIV/AIDS epidemic
in Los Angeles County.
Chapter 3 : Enterprise Level - Strategic Approach to Internal M&E
Considerations for a monitoring and evaluation system at a local health service provider
are different than that of an M&E system at the national or international level. This is naturally
true based on the fact that stakeholders (enterprise managers, government officials, donors) have
different sets of motivations and priorities. Though internationally accepted indicators and
guidelines help to standardize M&E across organizations and countries, the disparity in incentive
structures implies that the decision process to measure performance and the definition of relevant
indicators ought to look different at each level.
The data collected at a health care delivery organization ought to reflect the intents of the
portfolio of projects undertaken at the enterprise. This means that organizations should create
and track indicators that are aligned with the strategy and goals of the organization's activities.
These project-level indicators theoretically provide a foundation to aggregate data for higher
order use at the national and global levels. Not all project-level indicators may be useful for
regional or national level monitoring and evaluation. However, a subset of them should be
applicable for higher-level aggregation.
Figure 11. Information Needs and Tools at Different Levels of Data Collection
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Source: WHO Health Metrics Network, Frameworks and Standards for Country Health
Information Systems, Second Edition (WHO Health Metrics Network, June 2008)
As described above by the Health Metrics Network, facility level data collection should
focus on facility management, audits, planning, and drug procurement. This data should be
drawn from facility registers and logbooks. To go one step downstream, patient care data
collection should be extracted from patient charts, probably located at the health clinic. This
information should feed into higher-level data collection needs.
Theoretically, an enterprise designs performance measures based on the organization's
strategic plan, the center of which would be the vision, mission, and core values. In this way,
organizations control what and how they intend to contribute value. However, in practice,
government regulations and funding requirements drive the data that is collected and reported.
By doing so, external stakeholders set the prioritization of activities and the configuration of care
provided by the local organization. In a phone interview with Brenda Rose of the AIDS Action
Committee in Boston, I learned that even the HIV/AIDS care program in a Boston, where health
resources are abundant, struggles to collect internally useful data. Instead, they collect data for
national reporting and grant proposals. In fact, the AIDS Action Committee is looking to replace
their current data monitoring system (Rose, 2011).
The process of fulfilling donor requirements often overwhelms M&E efforts within local
service organizations to a point of preventing other attempts at internal monitoring. However,
this cannot be a valid excuse to completely replace efforts on internal data tracking with those
requested by external stakeholders because external stakeholders may emphasize different
priorities than those that should be in place for the service provider organization.
For instance, international organizations fundamentally focus on aggregate level data,
such as national compilations or regional collections of their portfolios. As explained in the
2010 UNAIDS Introduction to Indicators Manual, "in general, national and global-level
indicators are not designed to measure the effectiveness of specific activities or to support the
day-to-day management and implementation of activities" (UNAIDS, 2010).
As one service organization that may be among a portfolio of enterprises that receive
funding from the same source, the service provider needs to identify its own competencies and
unique strengths. Because funding may come and go by the election or whim of politicians
overseas, financial survival is difficult to guarantee. Therefore, knowing and articulating ones
strengths and purposes is important to maintaining a stable identity and focus, rather than
allowing the organization to fundamentally fluctuate based on availability of resources. Beyond
minimizing internal management chaos from shifting resources, structuring activities based on a
central strategy is also useful for advocating the organization to potential supporters. As part of
this attempt to internalize management decisions, it is vital for organizations to develop a set of
indicators that are specific to the purposes of their unique activities, regardless of those
demanded by external stakeholders, who may have higher-order perspectives.
Each health care delivery organization faces different inputs reflecting the health needs in
the community and the capacity by which the organization can fulfill those needs. Though we
can categorize the types of inputs to an extent, the combination of characteristics lead to very
different answers as to the best course of actions to take. Best practices, therefore, are often
difficult to generalize. Therefore, instead of suggesting an absolute answer, I look to experts for
advice on how an organization should approach strategy. The following section introduces one
expert framework, the care delivery value chain, for understanding health care delivery.
3.1 Care Delivery Value Chain
The portfolio of activities that a health care delivery organization undertakes reflects a
chosen scope of care delivery. The scope can be medically integrated across specialties,
treatments, services, or time. Determination of this range and focus informs management needs
for coordination, goal setting, and maximization of value for unit cost. The Care Delivery Value
Chain (CDVC) is a framework for understanding the configuration of care delivery, focusing on
one medical condition at a time (Porter & Tesiberg, The Care Delivery Value Chain:
Operationalizing Value-Based Health Care Delivery, June 2008). The value chain depicts
treatments and procedures by medical stage of that condition. Listing the activities along a value
chain shows us how the players, activities, and stages of care relate to one another. The
framework displays the integrated nature of care delivery for a specific health condition. By
visualizing the many facets of care, we can attempt to organize care delivery within a common
understanding of comprehensive care. Furthermore, we can begin to understand and define
success of a health care delivery program in the context of the entire care pathway. Implications
of this exercise include management's improved ability to structure performance monitoring and
evaluation within a chosen scope of care delivery. The figure below describes the components of
a care delivery value chain and what each part entails.
Figure 12. The Care Delivery Value Chain
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The care delivery value chain begins with monitoring/preventing, which is valuable for
early detection and minimization of needed treatment. Focus on preventative care reduces
potential medical costs. Diagnosing occurs when a patient is tested and evaluated. An
effectively organized and recorded diagnosis process becomes valuable for sharing information
in further consultations and across integrated care practices. Preparing is a step that is often
overlooked in importance. The actions taken at this stage include mentally, physically, and
financially preparing the patient and relatives. The impact of adequate preparation includes
better execution of interventions and improved results. Intervening includes the activities taken
to treat a condition. This step of the value chain includes the entire set of interventions needed,
which can be looked at individually or analyzed as a combination of integrated interventions.
Recovery/rehabilitating, like preparing, is a step that is often overlooked in terms of attention
and significance. Sufficiently recovery and rehabilitation improves results and reduces re-
hospitalization, thereby decreasing overall cost. This aspect of the value chain provides
psychological, physical, and resource support. The final stage of care delivery is continuous
monitoring/mnanaging of the patient's condition. This step is valuable for identifying potential
needs to re-visit earlier stages of the care delivery value chain in the event of complications.
Monitoring and management involves improves long-term results and reduces the need for
additional care (Porter & Tesiberg, The Care Delivery Value Chain: Operationalizing Value-
Based Health Care Delivery, June 2008).
In the care delivery value chain, patient value is defined as health results per unit of cost
(Porter & Teisberg, Redefining Health Care: Creating Value-Based Competition on Results,
2006). In addition to depicting the steps in a care pathway as a condition progresses, the care
delivery value chain also points out the different aspects of knowledge management that must
occur at each step in the value chain. These three aspects are assessing, measuring, and
informing. The following diagram explains each of these three components.
Figure 13. Knowledge Management Along the CDVC
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The impact of having controlled and sufficient knowledge management is increased
participation of the patient in his or her own care management. Active involvement and
investment of the patient in his or her care usually leads to more successful outcomes as a result
of managed expectations, self-monitoring, and early detection of complications or gaps in care
delivery (Porter & Tesiberg, The Care Delivery Value Chain: Operationalizing Value-Based
Health Care Delivery, June 2008). Therefore, systematic efforts taken towards identifying and
improving knowledge management can be valuable for care delivery and should be tracked along
the value chain.
In order to reap the benefits of this tool, providers need to systematically delineate and
analyze their process of care delivery for the entire care cycle rather than for a particular
intervention or service. Providers engage in many activities that deserve management attention.
Formal identification of activities and knowledge development by health care providers are
crucial to increasing value (Porter & Teisberg, Redefining Health Care: Creating Value-Based
Competition on Results, 2006).
3.2 CDVC for HIV/AIDS
Applying the care delivery value chain framework to HIV/AIDS, the six components of
the CDVC are categorized into Screening/Preventing, Diagnosing/Staging, Delaying
Progression, Initiating Antiretroviral Therapy, Ongoing Disease Management, and Management
of Clinical Deterioration.
Screening/Preventing consists of connecting the population to a care system, promoting
prevention and testing. At this level, accessing patients occurs at testing centers, clinics, and
educational outreaches. Measuring involves HIV testing and collecting data. Informing and
engaging the population includes counseling and educating at-risk populations.
Diagnosing/Staging involves the formal diagnosis of HIV. The patient is checked for co-
infections, assessed for HIV stage, and then a treatment plan is formulated. The patient accesses
care at clinics and laboratories. Measuring includes having a CD4 count measured. Patients are
informed of the diagnosis and the course of HIV.
Delaying Progression of AIDS is possible through therapies that delay onset. Patients
are put on prophylaxis and monitored consistently for co-morbidities at clinics. During this
stage, patients can be plugged into support groups and engaged with community health workers
that monitor psychological and physical health. Access sites also include pharmacies and
laboratories, where medical status and CD4 counts are measured. The patient is informed of the
progression process and their personal progression (Porter, Value-Based Health Care Delivery,
2010).
Figure 14. CDVCfor HI V/AIDS Part 1
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Initiating Antiretroviral Therapy occurs once the disease progresses to the point of
needing ART. Patients must be prepared for the effect of drugs. Patients still access care through
clinics, laboratories, pharmacy, support groups, and community health workers. Measuring
consists of monitoring medication response, laboratory tests, and managing possible
complications. Patients are informed of medication instructions and side effects.
Ongoing Disease Management consists of continual monitoring of treatments, co-
infections, and preparing for future steps. Patients are measured for medication response,
general health assessments, and laboratory tests. They are informed of consequences of non-
adherence and counseled for support and assistance.
Management of Clinical Deterioration is necessary and inevitable because AIDS has no
cure. As the disease progresses, patients need to prepare for end-of-life care. Therefore, access
sites expand to include hospitals, hospice facilities, and services that specifically deal with
emergency response. Patients are measured for HIV stage, medication response, laboratory tests,
and potential acute illness or opportunistic infections. Patients must be engaged and informed of
the status of their condition, so that preparations can be made regarding end-of-life arrangements
and counseling (Porter, Value-Based Health Care Delivery, 2010).
Drawing out the entire HIV/AIDS care delivery value chain allows us to visualize the
activities that are involved in the care of an HIV patient. Health care delivery organizations may
choose not to participate in every aspect of the value chain and, instead, specialize in one aspect
of care. However, it is important to understand how seemingly discrete actions are integrated
into a whole process within the care pathway. Additionally, focused care delivery can have
implications that exceed the seemingly narrow scope. For instance, early diagnosis through
regular testing and monitoring can help to forestall disease progression. Also, improving
compliance via patient engagement reduces drug resistance and the cost of second-line therapies
(Porter, Value-Based Health Care Delivery, 2010).
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Defining the scope of care delivery at the service provider level is important for
monitoring and evaluation purposes. While external organizations may have requirements and
guidelines for choosing indicators from the perspective of the entire value chain, internally,
management will create a strategic plan based on the scope of care that the organization chooses
to deliver. The indicators that are tracked for monitoring and evaluation purposes should
specifically reflect the selection on the value chain and consider how that part relates to the rest
of the value chain.
The choice of indicators and performance measures reflects a decision regarding
prioritization of care activities. Each decision, intentionally or not, exerts a definition of success
and an emphasis of the output, outcome, or impact that is important to the service provider.
Therefore, laying out the CDVC for AIDS can be useful to illustrate these decisions and efforts
made by the organization. Rather than adopting a set of recommended indicators, the
organization should actively control its scope of care, the value it wants to deliver, the change it
hopes to effect, and the part of the landscape that its activities aims to alter.
3.3 Comprehensive Approach to HIV/AIDS Care Delivery
Traditional business strategy would suggest that in order to get the most value from a
limited set of resources, an organization should specialize in a specific part of the value chain.
Scope should be determined by the core competencies of the enterprise, and energy should be
focused to exploit that advantage in order to bring the highest potential value to the market.
Enterprises should leverage the supporting organizations that focus on other aspects of the value
chain, so that a network of specialized service providers complete the entire chain to bring the
patient comprehensive care within a system of health care delivery organizations. However, in
the case of many health care organizations in developing settings, the supporting infrastructure is
not well established. Therefore, only supplying one aspect of the value chain will not sufficiently
bring value to the patient.
When designing a care model for HIV/AIDS, the service provider must consider the
complexity of addressing the needs of a patient. Providing comprehensive care should involve
multitude of entities that contribute to the system of health care. The following diagram
illustrates the continuum of care that is necessary to care for a patient living with HIV/AIDS.
Figure 16. HIV/AIDS Continuum of Care
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Source: FHI, Evaluating Program for HIV/AIDS Prevention and Care in Developing Countries:
A Handbook for Program Managers and Decision Makers (Family Health International, 2006)
According to FHI, comprehensive HIV/AIDS care is provided over a continuum of care,
involving testing sites, primary health care, community groups, home care, peer support, and
secondary and tertiary health care providers (Family Health International, 2006). Because the
different players in this system have different roles in HIV/AIDS care, they each have their own
strategies and M&E designs to measure individual success. We can look at overall impact by
evaluating the entire system, but to analyze the individual parts, data monitoring focuses will be
divided among the stakeholders.
Chapter 4 : Kyetume Community Based Health Care Programme: Case
Study
Kyetume Community Based Health Care Programme (KCBHCP) is a faith-based health
care organization located in the Mukono District of Uganda. It serves two subcounties,
Nakisunga and Ntenjeru, within rural Mukono and has a catchment size of over 100,000 people.
The mission statement of KCBHCP is "to improve the general health standards of underserved
rural people within Mukono District and Uganda at large by influencing behavior of rural
communities using a community based involvement/participatory approach" (Kyetume
Community Based Health Care Programme, 2009). At the core of the organization is the
principle that providing health services in the community requires an integrative perspective to
care, demanding social as well as economic support in order to sustain physical health. This
model of health care delivery is not new, with celebrated organizations such as Partners in Health
also pursuing education, community involvement, and social and economic development in
addition to providing quality medical services (Partners in Health, 2011).
KCBHCP was founded in 1992 as a group of Christians who met under a mango tree
outside a local church, educating the community on the importance of hygiene and healthy
practices. Since then, KCBHCP moved into a house, where health services could be carried out.
The scope of the organization grew from Maternal and Child Health to include primary care,
immunization, and antenatal care. In 1997, the HIV/AIDS Program was officially defined.
KCBHCP began to offer income-generating vocational training programs in 2000. By 2007,
KCBHCP ran more than six different activities including the Oxfam funded Gender-Based
Violence Program (Kyetume Community Based Health Care Programme, 2009). Currently,
KCBHCP provides home-based care to more that 560 HIV positive clients, with over 100
individuals counseled and tested every month.
4.1 Integrative Health Strategy
As of 2011, Kyetume Community Based Health Care Programme is made up of seven
overarching programs: HIV/AIDS, Maternal and Child Health, Gender Based Violence, Sexual
and Reproductive Rights Promotion, Water and Sanitation, and Orphan and Vulnerable Children.
Within the Orphan and Vulnerable Children program are a number of projects, including the
Orphan Support Project that provides households with cows and goats for income generation;
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Agriculture that provide training for organic farming and creation of keyhole gardens;
Vocational Training Programs for developing income generation skills in tailoring, hairdressing,
computer skills, carpentry, and automechanic skills; Child Counseling and Guidance; and
Microfinance. The Orphan Support Project alone has benefitted over 900 orphans to date. The
activities of KCBHCP are tied together by the underlying principle that the issues addressed by
each program are interrelated. The belief is that addressing the determinants of health and
patient behavior is key to improving the overall health of the community.
Applying the care delivery value chain to KCBHCP, we can see that KCBHCP
participates in six categories of the HIV/AIDS care delivery value chain. Prevention efforts
include running sexual and reproductive health education classes at schools. VCT occurs at
clinics as well as during outreach activities in the local community. Patients are counseled
before and after the test. For diagnosing and staging, lab work and designing treatment plans
occur at the health facilities, where lab technicians, doctors, nurses, and counselors work
together. KCBHCP provides services during the delaying of progression, which include co-
infection testing, drugs, education, and support groups. Initiation of ART is supported by the
Ugandan government's policy on free ARV drugs. KCBHCP is very active for ongoing disease
management. Adherence is monitored when CCAs go out to the community to check on patients.
KCBHCP is less involved in the management of health deterioration, though they provide
counseling for family members, including child counseling and OVC support programs.
From a distance, KCBHCP's strategy to engage in so many activities can seem to be
unwise. Critics may claim that having such a broad focus spread already limited resources even
thinner and that without a narrow focus, innovation and the development of competencies
become slowed. However, a closer look at the Kyetume community reveals the relationship
among education, income generation, ability to obtain health services, and willingness to
improve on physical health. The ability of a person to obtain medical care for HIV/AIDS
depends on their access to health knowledge and education, their ability to afford transport, as
well as their ability to sustain the social and economic wellbeing of the members of their
household. Understanding this concept is critical to why having a strategy of integrative model
of health care is logical and necessary for raising the health of this community. In more
developed parts of the world, a network of enterprises and established public infrastructure
support community health so that an organization can achieve its vision for improved community
health by focusing on one aspect of health care delivery. However, the absence of this strong
network requires KCBHCP to address the social and economic aspect of health development in
order to sustainably raise the overall level of health for the people in their Mukono catchment
area. KCBHCP recognizes that providing health care in its community demands simultaneous
social development. With no other player stepping up to that challenge, KCBHCP takes on
responsibility that might ideally be the role of other organizations or the public sector. Whether
or not this is a realistic or sustainable objective remains to be determined.
The KCBHCP strategy draws upon members of the community to participate in the
vision and mission of the organization. Community Counseling Aids'4 are community
volunteers that reach out to people that KCBHCP would otherwise be unable to affect. Having a
member of a person's own town speak to them can be a successful way to develop trust and
foster Kyetume's credibility in the community. This strategy to engage community members is a
key component to KCBHCP's success.
Though KCBHCP runs multiple programs, the HIV/AIDS program tends to dominate the
majority of KCBHCP resources. A reason for this is that the HIV/AIDS program receives the
most funding, which means that it is vitally important for KCBHCP to sustain these funds. In
order to do so, KCBHCP dedicates a significant amount of effort towards fulfilling donor
requirements, which in this case, is quite extensive and labor-intensive.
Figure 17. Kyetume Community Based Health Care Programme Annual Budget
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Source: KCBHCP, acquired on site, accessed March 2011
14 Community Counseling Aids are similar to accompagnateurs in the PIH model or Community
Health Workers in other health delivery organizations. However, accompagnateurs of the PIH
model are paid. CCAs at KCBHCP are paid minimally, but transport costs account for much of
the compensation, so the CCAs tend to work other jobs to sustain a living.
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4.2 Data Monitoring
The fact that KCBHCP covers such a wide range of activities that directly or indirectly
relate to the success of an HIV/AIDS program poses an interesting challenge for data
monitoring. The value proposition of the organization demands that community determinants of
HIV/AIDS be considered when deciding upon indicators to track and formulating the measures
for performance evaluation. However, the data collected at KCBHCP, like many grant-dependent
health care organizations, are donor determined and standard to HIV/AIDS programs regardless
of the care model.
KCBHCP's HIV/AIDS program is funded by the Inter-Religious Council of Uganda
(IRCU), which receives money from USAID/PEPFAR. IRCU's aim is to strengthen FBO"
capacity to plan, implement and deliver community based HIV and AIDS services while building
on existing structures and unique experiences (The Inter-Religious Council of Uganda ).
However, as a PEPFAR funded donor, IRCU demands detailed monthly reports from KCBHCP
based on pre-established PEPFAR criteria (see Appendix G). The data demanded by IRCU is
generic to all HIV/AIDS programs funded by PEPFAR and not catered specifically to
KCBHCP's situation. The process of data collection and reporting for these given indicators is
tiresome and resource consuming (Kibirige, 2011). A lot of energy is spent on fulfilling donor
requirements for funds that are essential to keeping the program running. As a result, relatively
little time has been allocated towards developing an internal monitoring system that is specific to
KCBHCP's strategic needs. In this sense, KCBHCP reflects a sentiment that has been repeated
in interviews (see Appendix H) in that the entire HIV/AIDS data-monitoring program is defined
by donor requests rather than having been built from internal organizational strategy.
From an objective management perspective, externally imposed data monitoring is not
ideal M&E. As mentioned in the introduction, M&E should be tailored to internal strategy so
that it is appropriate and comprehensive for the purpose of the organization. However, because
the existence and continuation of operations and activities depends 100% on donor funding,
health care service enterprises such as KCBHCP often end up catering its activities to where the
money is, despite initial strategy. With the need to adapt activities to funded projects, grant-
dependent organizations have a fundamentally difficult time sticking to their original plans if
those plans don't perfectly coincide with donor agendas.
15 "FBO" is an acronym for faith-based organization.
Additionally, the need to fulfill donor requirements becomes even more stressful with
resource constraints making the data collection and reporting process labor intensive. With
unreliable availability of electricity and limited number of working computers, Access databases
and intranet linked computer data input systems become impractical and unrealistic. Therefore,
the staff at KCBHCP must devote precious time and work to shuffling through paper documents
and filling out forms one at a time. The paper-based system is a reality due to infrastructure
constraint. Because PEPFAR has one set of requirements standardized for all types of settings,
the burden of fulfilling donor requirements sits more heavily on some organizations than others.
4.3 HIV/AIDS Program Data Collection and Reporting
Counselors, lab technicians, nurses, and doctors fill out forms on a daily, per patient,
basis. On a monthly basis, they each need to fill out multiple monthly forms, which compile
some of the information recorded on daily forms. These monthly reports are then submitted to
the KCBHCP data officer and M&E program manager, who put together the forms that are
eventually delivered to external stakeholders, such as donors, the Ministry of Health, and other
regional government offices (Kibirige, 2011).
Figure 18. Kyetume Community Based Health Care Programme Reports
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Currently, the only process that is computerized is the creation of the internal monthly
report and the MEEP reports. Excel is used to create charts based on the data inputted into the
computer from daily and monthly forms, which are hand-written by staff.
Although IRCU (via PEPFAR) and the Ugandan Ministry of Health have both indirectly
been involved in UNAIDS MERG attempts to streamline data indicators and M&E processes,
the fact that both parties require separate report forms remains a problem. It is burdensome for
KCBHCP to fill out so many forms with a paper-based system because each data point requires
looking through stacks of paper files. A complete list of indicators collected by KCBHCP is
presented in Appendix H. This process is labor-intensive and, arguably, poorly spent time for
clinicians and counselors who can otherwise be attending to clients (Kibirige, 2011).
The assertion that external donors dictate KCBHCP's data monitoring was confirmed
during the Global Health Delivery Lab's two week on site project at Kyetume. The primary aim
of the project was to help develop and improve upon the existing data monitoring process at
KCBHCP. Our focus was to start with the HIV/AIDS program and transfer the findings, thought
process, and tools to other KCBHCP programs with time permitting.
We quickly learned that IRCU's requirements for the HIV/AIDS program led to time-
consuming efforts to track over 300 indicators. For KCBHCP, the purpose of data collection
seemed to be to submit reports rather than to conduct analysis and discussion on internal
improvement. In comparison, the OVC program doesn't require such rigorous reports to be
submitted to donors on a regular basis. As a result, the M&E for the OVC program is purely
qualitative in nature, doesn't have a formal list of indicators to track, and appears dwarfed next to
the lengthy number-heavy HIV/AIDS reports. This, however, is not representative of the
importance and impact that the OVC program carries for KCBHCP. Considering the core values
of integrative care and support as well as community involvement, one would think that the OVC
program ought to have a level of M&E equal in quality and resource consumption in order for
internal management to measure and improve upon performance. A third interesting example is
the relatively sophisticated M&E system developed for the Gender Based Violence Program,
which is funded by Oxfam. Oxfam-driven M&E demands more than routine data collection
from its partners. The donor organization involves the GBV program staff to learn about the
purpose behind their M&E efforts, fostering ownership, investment, and quality check. Oxfam
directly conducts evaluations on program perfonnance, participates in discussions about strategy
and activities, and involves GBV staff to improve their own capacity through teaching and
guidance (Kayondo, 2011).
Seeing the three uneven levels of M&E development within one overarching organization
was a bit surprising. However, the existence of this disparity signals clearly that M&E was an
external influence and imposition rather than something that grew organically from within.
4.5 Lessons Drawn From KCBHCP
KCBHCP is an example of how M&E tends to be established for the sake of donor
reporting rather than for internal improvement. The separation between data collection and
internal strategy results in meaningless data collection for the sake of data reporting. Without
ownership and intentional M&E from within the organization, M&E becomes purely about
obtaining resources and funding whereas in other grant-independent organizations, M&E is an
effective management tool.
The GHD Lab team's aim was to help KCBHCP by exploring the disconnect between
what is being done and the potential for how those actions can be leveraged through intentional
efforts towards internal improvement. The common problem of strictly donor defined data
monitoring shows that this aspect of global health delivery has been slow to develop and is only
now adapting established management expertise for donor-dependent development
organizations.
However, it is important to also note that fault should not be placed on enterprise
management. As explained by KCBHCP Programs Manager, Reuben Mubiru, the process of
fulfilling donor requirements is painfully time and resource consuming. Intentionally or not, the
funds and contingencies related to resource needs end up driving strategy and organizational
operations. While KCBHCP would like to spend more time pursuing client work, the programs
don't exist without the money to fuel them. In this way, program managers have their hands
tied. When asked to describe the effect of the data reporting process, Mr. Mubiru said it "limits
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their ability to innovate," which, reflecting an issue raised in expert interviews, voices a common
concern among grant dependent health care delivery organizations (Mubiru, 2011).
4.6 Broader Implications of the KCBHCP Experience
It is not uncommon for health care delivery organizations in developing areas to begin
with one program with one purpose and then expand to delivering supporting services. For
instance, KCBHCP's first program was Maternal and Child Health. This included PMTCT
services and HIV/AIDS treatment and prevention. As the organization realized that
beneficiaries' health behaviors were related to their economic situations and that the well-being
of orphans and vulnerable children were being neglected and marginalized, KCBHCP began the
Orphan and Vulnerable Children Program. Eventually, this program grew to providing animals
and farming education for income generation. While this type of organizational growth can be
understood as fulfilling needs in the community, the truth is that delivering maternal and child
health services is quite different from teaching household caretakers to start a small garden.
From my perspective, the act of expansion is not the key problem, but rather the lack of strategy
and thoughtfulness regarding organizational capabilities.
An enterprise with a strong management core recognizes that a balance needs to be struck
between the needs in the community and what the enterprise should realistically provide. For
transferrable resources, the cost to performing one function normally takes away from
performing other functions when resources are limited. For instance, organizational budget,
facility space, and employees' time needs to be shared among the various activities. When an
organization's activities are dissimilar, the skills and resources needed are not necessarily
transferrable among all programs. For instance, the same doctor or nurse can provide treatment
for HIV and TB. However, the expertise required for raising heifers and goats will uses a
different skill set than delivering medical services. The equipment and supply sources for
agriculture are not the same as for clinical services. The management needs for these various
programs, thus, are also different. Therefore, an organization's ability to be successful in one
program, does not guarantee that it will be successful in another endeavor, especially if the
second program requires dissimilar capabilities. The decision to expand activities for a donor-
supported service provider ought to consider the organization's core competencies.
The revenue stream for an organization such as KCBHCP comes from external donors,
not from beneficiaries. In other words, revenue is not tied directly to the value that beneficiaries
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receive through services provided by KCBHCP. By requiring regular reports, donors make
efforts to connect organizational performance to the amount of funds given. However, by the
nature of this arrangement, the NGO's incentive structure is a delicate balance between donors
and beneficiaries. Theoretically, donors should have beneficiary needs in mind when designing
indicators and performance measures. However, due to other reasons mentioned in this paper, the
realization of this intention is complicated in reality. As differences arise between what donors
envision and what organizations believe is best for the beneficiary, the incentive for the NGO
incrementally evolves to either satisfy donor requirements or to satisfy beneficiary needs.
For an organization like KCBHCP whose vision is to raise the overall health of the
community, the scope of services should theoretically consider the needs of the beneficiaries and
the organization's capabilities to serve the community. However, when a large sum of donor
funding is tied to HIV/AIDS services, then it becomes understandable for the service provider to
dedicate more effort to the HIV/AIDS program. Additionally, since the process of filling donor
reports is resource-consuming, time, effort, and manpower is taken away from other activities
within the organization.
The importance of balancing donor-driven priorities and organization-driven priorities
cannot be more highly emphasized. In order for a health care service delivery organization to
not sway to and fro based on funding availability, it is extremely important for the organization
to keep to a centering principle and have a strategic plan as an internal guiding force. This can
be in the form of periodic management reviews on activities to check if the organizational is
staying true to its own vision, mission, and goals.
4.6.1 Balancing Stakeholders
Donors and health care delivery organizations share a common goal to decrease the
burden of HIV/AIDS at the beneficiary level. Donors expect to do so by financing local service
providers who act on the shared objectives and motivations. However, in reality, the issue of
which stakeholder should lead the service agenda becomes a topic of contention. The service
provider, by nature of being local, can argue that they have a better sense of beneficiary needs.
The donor organization can argue that they have experience with multiple health care delivery
organizations to expect specific outcomes based on a set of standard criteria and practices. Yet,
this conflict for priority setting and legitimacy of decision makers is complicated by the fact that
both parties need each other. Large donor organizations are not equipped to develop health care
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delivery services in multiple places around the world. They need to leverage the know-how of
existing local enterprises instead of spending valuable resources replacing them (Kakuhikire,
2011). Likewise, service providers cannot function without the money and resources offered by
donor groups, so they are obligated to cooperate (Mubiru, 2011).
There are three key points that must be addressed in order to relieve some tension
between donors and local health delivery organizations. First is that a balance between trust and
caution must be struck. The fact that service providers and donors need each other to reach a
common goal requires a partnership to be established. An effective partnership, like most
successful relationships, is based on trust that both parties are working towards the same purpose
and that both have a legitimate role in this purpose. Yet, because they are two separate entities
with different organizational incentives, caution must be taken to check that the actions being
required and taken are aligned with both parties' interests in mind. For instance, service
providers need to take the time to fill out regular reports to donors. However, if this process
becomes unreasonably tiresome and takes away from the ultimate goal to provide better service
to the beneficiaries, then perhaps the donor organization should rethink its requirements.
Second is that negotiation power must be shared. For the sake of ownershin and buv-in
the health care delivery organization must have some participation in the activities of its
organization, which is true beyond the purpose of monitoring and evaluation programs. Also,
the donor organization needs to keep a continual learning feedback loop so that it can better
understand the needs and concerns of beneficiaries and service providers (Kakuhikire, 2011). By
allowing some negotiation to occur regarding M&E data collecting and reporting, the donor
organizations can better tailor their standard indicators and performance measures to be
appropriate and effective.
Third, donor level control of a health care enterprise's activities must be allow for a
degree of freedom to innovate. While one can understand a donor organization's concern over
the uses of given resources, the service provider must be allowed some space for creativity. As
with KCBHCP, the current donor-service provider relationship is tightly controlled, where
money is provided for stated and reported activities, with little room for discussion or
experimentation (Mubiru, 2011). The growth of an enterprise is tied to its ability to explore
activities, possibly fail, and then learn to better capture market needs at lower costs. However,
innovation is often constricted by the few activities that donor organizations choose to finance
and the weight of reporting duties tied to that money.
4.6.2 Resource Limitations
For organizations that depend 100% on donor funding, satisfying donor requirements is
held at the highest priority (Mubiru, 2011). Securing funds is equivalent to securing fuel vital for
survival. Unfortunately, the combination of the heavy load of paperwork and resource
limitations makes the burden of fulfilling donor requirements extremely heavy.
The fact that global health actors are recognizing the need for M&E is a step in the right
management direction. However, the development of effective M&E has been a slow and
cumbersome process that still needs massive improvement. In the developed world, we can take
for granted the convenience of technology and the implied efficiency gained through
technological innovations, such as new computing software or electronic databases. In our world
of ever-present computers, people are expected to be able to pick up and use new technologies
that make our work easier. Even in the United States, technology has not been a cure-all solution
to the inefficiencies of the American health care system. However, the ability to store medical
records, communicate with patients, share documents, compile data, and analyze statistics are
very much technology dependent and extremely important to improving speed and efficiency of
health care provision.
In the developing world, where even electricity and running water are not dependable,
different methods for health care solutions must be utilized. When computers, expensive
software, and people who can comfortably use such technology are unavailable, the solution to
improved health care provision, monitoring, and evaluation (at the local level) must be one that
is tailor fit to the local situation. Moreover, these answers need to be in a format that is
transferrable and translatable to district, national, and donor level requirements.
There are two ways to solve this conundrum of increasing the ease of reporting without
deteriorating the quality of data. The answer lies either with the local provider or with the donor.
Either, the health care delivery organization finds a way to better effectively collect and report
data, or the donor lessens the burden of the requirements. It is necessary to strive for a balance
between achieving sufficient data and having reasonable expectations for a resource-constrained
enterprise. Reducing this tension requires having the freedom to negotiate custom fit reporting
details for individual organizations. Another option would be to come up with a set of data
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requirements that is somehow suitable for all organizations. Considering the variety in health
care delivery type, scope, and context, I do not find this second option to be realistic, practical, or
appropriate.
4.6.3 Internal Data Management
As is true with all enterprises, internal management must drive the functions and
operations of the organization. Management in the non-profit sector differs from the for-profit
sector in that profits are not the only deciding factors for organizational survival. Consequently,
the fact that beneficiary-driven revenue and outcomes don't drive survival and competition
means that innovation, learning, and continuous internal improvements aren't given as much
emphasis as they typically are given in for-profit enterprises. The problem with this is that
efficiency and cost-effectiveness of spent resources are not directly reflected in the
organization's ability to function. Therefore, many of these organizations don't place enough
emphasis in measuring performance and cutting activities that waste valuable resources.
Managerially sound performance measures are designed internally, based on the
organization's strategic plan. Metrics for evaluating progress towards organizational goals and
program objectives ought to be determined simultaneously with goal setting to make sure that the
goals are specific, measurable, achievable, realistic, and time-framed (SMART). In this way, the
organization defines what it aims to achieve and how it plans to do so. An advantage of having
the local service provider determine performance measures is that it can consider local context,
unique beneficiary needs, and its own resource limitations and core capabilities. I argue that,
regardless of M&E requirements demanded by an external party, every successful health care
delivery organization must create and maintain a self-determined, custom-fit, and self-owned
internal monitoring and evaluation program. Perhaps external parties' M&E requirements can be
incorporated into the organization's internal M&E program for efficiency sake, but the health
care organization cannot easily stay focused on its core mission without having a stable self-
monitoring and evaluation system in place.
Data gathered from this M&E system is designed to be reflective of the strategic plan and
uses indicators that are useful for the organization itself. The management team will be able to
measure the organization's progress at achieving stated goals, selecting the activities that are
successful and others that are not. Ideally, actions can be taken to either improve or cut activities
that do not generate sufficient value. Because the indicators are self-defined, they are consistent
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to the organization's core versus set to the priorities of external parties. Furthermore, while
donor organizations may change over time, district and national reporting requirements adapt,
and international guidelines affect new standards, the internal M&E of an organization adapts to
its own pace and requirements, which helps to stabilize the internal operational and keep the
management focused.
4.6.4 Dashboard
To assist KCBHCP develop internal data monitoring, the MIT Global Health Delivery
Lab team created a tool for the organization that can be relevant in other HIV/AIDS care delivery
organizations. The concept is to create a dashboard of key indicators that the organization can
track, so that management can get an idea of performance with a quick glance. The current
approach requires flipping through long documents and files, which becomes intimidating to a
point of dismissing review altogether. The dashboard is meant to offer a summary understanding
of organizational performance based on aggregation of chosen indicators. Longitudinal analysis
shows general trends toward or away from set targets. In this way, Excel automated graphs can
ring managerial alarms for poor performance or identify successful activities.
Dashboard indicators should reflect the priorities set by the service provider's
management team. The dashboard indicators chosen for KCBHCP were based on discussions
with the management team at KCBHCP. In these discussions at KCBHCP, we asked the staff
what indicators they were mentally tracking, which indicators they felt were important or
indicative of program success, and which indicators they automatically looked for in reports. We
cross-checked the answers among the different staff members by looking for repeated answers
by KCBHCP staff, reviewed commonly used indicators from external sources and expert
interviews, and screened each of these indicators for logical sense within the organization.
Finally, we picked out the indicators that were stated most frequently.
Figure 19. KCBHCP HI V/AIDS Program Monitoring Dashboard - Sample
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Based on interviews with PACT at Harvard School of Public Health and with the
Manager of Health Surveillance and Evaluation at Partners in Health, I learned that PACT has
also adopted a dashboard-like process of program monitoring. Some key indicators that PACT
tracks per patient and on a monthly basis include number of hospitalizations, frequency of
facility and ER visits, and CD4 count (Gomez, 2011). PIH uses percentages to obtain meaningful
statistics from the data collected at their facilities. For instance, one of the dashboard indicators
tracked by PIH include the percentage of patients who test positive and enroll in the same period
(Peckarsky, 2011).
The adoption of a dashboard cannot replace full program reviews based on collected data.
The dashboard is simply a starting point to visualize program progress. In comparison to the
minimal internal data monitoring currently in place, this type of tool can prove useful for a health
care delivery organization to reflect on its own performance in a way that is managerially
beneficial. Though the focus here has been on data monitoring, the importance of evaluation
cannot be overlooked. As an organization matures, it becomes increasingly important to monitor
its impact on beneficiary mortality, morbidity, and quality of life. The purpose of this is to
evaluate effectiveness and efficiency of the organization's activities. The data gathered through
evaluation can be used to legitimize the organization's presence in the community, confirm the
necessity of continued funding, and affirm stakeholders' support.
Chapter 5 : Conclusion
Thus far, I have defined monitoring and evaluation in HIV/AIDS care delivery, providing
example of M&E applications. In Chapter 2, I presented global level stakeholders who
participate in shaping M&E practices in HIV/AIDS care delivery. As discussed in that section,
multiple organizations offer guidelines, tools, and requirements for HIV/AIDS M&E. While the
performance measures presented in these documents often overlap, the processes of data
reporting are not the same across donors. Chapter 3 discussed HIV/AIDS M&E systems at the
enterprise level. The purpose of that section was to describe how M&E design fits in with
organizational strategy. In Chapter 4, I presented Kyetume Community Based Health Care
Programme as a case study on data collection and monitoring challenges at the service provider
level. KCBHCP's experience raises the question of the cost of fulfilling donor requirements to a
resource-constrained health care delivery organization. Reflecting on themes from the previous
chapters, this section discusses the interaction between global and enterprise level stakeholders
and the implications to monitoring HIV/AIDS care delivery.
5.1 Cost of Multiplicity and the Need for Better Coordination
Today's complex global health problems require responses from the level of global health
governance to the local service provider. Multilateral agencies, governments, and NGOs have
stepped up to the plate, making such contributions as increasing funding, drug availability, and
access to health services. Yet, without effective communication and collaboration, the abundance
of new resources and efforts end up costing unnecessarily exorbitant amounts of money, time,
and human resources. A study by McKinsey and the Gates Foundation identified five benefits of
global health partnerships (Cahill, Fleming, Conway, & Gupta, 2005): pooling resources to
enable higher-risk activities that individuals would take alone, sharing of knowledge and
resources, producing economies of scale, avoiding duplication of investments and activities, and
increasing legitimacy and support for funding and momentum. The movement towards more
coordination among the multitude of global health actors has seen the rise of more than 70 global
health partnerships between 1995 and 2005 (Cahill, Fleming, Conway, & Gupta, 2005). Without
coordination, individual organizations develop separate preferred structures and practices. This
environment of independent players is similar to a room full of people who are talking, where
valuable messages are drowned out and a coordinated strategy becomes difficult to achieve.
Monitoring and evaluation protocols for HIV/AIDS programs are affected by the
disorganization of the global health system. A lack of a leading voice to direct and establish
structure among the plethora of guidelines and practices leads to difficulty deciphering the
players and publications that are current and relevant. Furthermore, as each government agency,
donor, and stakeholder demands its own data reports, the burden to collect and report on data
becomes increasingly heavy for the local health care delivery organization. Monitoring and
evaluation processes, though important, are resource consuming, which means that unnecessary
duplication of reporting efforts becomes very costly for the organization.
Improvement in M&E collaboration in the form of shared knowledge and reporting
protocol among the different stakeholders could significantly reduce the burden on the local
service provider. Perhaps reporting formats can be standardized at the international and national
levels, where large donor organizations can come together to create a common structure to obtain
regular data reports, especially if their performance indicators are similar. An interesting point to
note is that with all the efforts in place to screen and improve new indicators, in my research, I
have not come across a mechanism to remove indicators. Similar to how an increasing number of
partnerships, programs, and guidelines are created to address health care issues, the improvement
and development of the system is missing a feedback mechanism to remove ineffective,
outdated, and excess entities.
There are few international players with the political and financial clout to influence
global agendas, though WHO, the World Economic Forum, and the UN Security Council have
all taken leadership roles for addressing HIV/AIDS in the past. Private foundations and
stakeholders such as the Bill and Melinda Gates Foundation and GFATM also have significant
financial and political influence. Furthermore, more than 50 public-private partnerships, such as
GAVI, have been established to battle infectious diseases (Ruger & Yach, 2009). The need for a
leader to organize these many global health actors is extremely important to better effectively
execute strategies to fight the AIDS epidemic.
To lead the collaboration and cooperation among global health players, I propose that the
WHO, which has the coordination mandate written into its constitution, be given the legitimacy
among the global health actors to effectively take on this role. I understand, however, that the
realization of this suggestion is complicated by the fact that every member state wants to
preserve its autonomy and that donor organizations will be hesitant to lose its credit for the
impact made through their individual efforts (Sullivan, 2011). Therefore, the very reason why
WHO needs to coordinate (too many other powerful players) is also the reason why WHO won't
be able to fulfill that responsibility.
5.2 Structural Weakness
The nature of the donor-enterprise-beneficiary relationship has a fundamentally skewed
incentive structure. Organizations that are 100% dependent on external funding are not free to
grow, fail, and learn in a process that is typical of most startup organizations in other fields.
When revenue is directly related to the services provided (beneficiary pays), the service delivery
organization can learn to maximize customer satisfaction and minimize cost in a way that is vital
to its survival. It is my opinion that entrepreneurships that preserve this character of business
have much more potential to survive, expand, and have true impact. Yet, I recognize the
difficulty (and, therefore, the shortage) of sustaining such health care organizations. The ability
for a financially self-sustaining health care delivery organization that serves the bottom of the
pyramid to exist, in a way that is replicable, is still uncertain.
In 2001, the so-called Harvard Consensus Statement stated, "AIDS treatment will always
be more expensive than poor countries can afford, meaning that international aid is key to
financing the effort." Furthermore, a 2010 Lancet article written by Robert Hecht, et al. echoed
the same conclusion that "low-income countries with a high burden of disease will remain reliant
upon external support for their rapidly expanding costs" (Ooms, et al., 2010). The dependency on
external funding does not appear to be diminishing anytime soon, which means that the payer
will continue to be disconnected from the patient in low-income settings.
The key, therefore, is to come up with an organizational innovation such that an
improved incentive alignment is built back into the equation. Based on my research through
readings, interviews, and experience at Kyetume, I believe that the underlying structure of the
current payer-provider-patient model hinders innovation. I have attempted to illustrate the
problem with separating the patient and the payer by constructing the following two diagrams.
The first diagram describes the conventional business enterprise model, where money is given in
exchange for services. The second diagram describes the donor dependent funding model, where
revenue comes from an external source separate from the patient. The provider submits
performance reports to the donors, who determine money allocation based on those reports.
Figure 20. Incentive Structure when Patient is Payer
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Money Money for Value +
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Organizational Survival Services Provided
Innovate or Die
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Actions for + Provided
Organizational
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Based on this diagram, we can see that the organization's survival is based on the amount
of money given to the provider, which, in this scenario, is determined by patient value. When
the organization feels that its survival is in jeopardy, the service provider is motivated to improve
itself such that the patient value is increased, perhaps through improved quality of services.
Figure 21. Incentive Structure when Patient is not Payer
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The diagram assumes that patient value translates to desirable performance results on
reports to the payer in such a way that the payer's willingness to pay increases. According to this
diagram, the service provider can assume that more of the same services will lead to patient
value, which leads to better reported performance results that bring in more revenue. In reality,
patient value is determined by a combination of the number and the quality of the services
provided. The service quality is determined by a number of factors not depicted in the diagram.
Perhaps the donor can motivate better services or hinder the provider's ability to innovate with
service (and therefore performance) changes. Or, perhaps, the provider has the flexibility and
resources to experiment with improving service quality to increase patient value. The key thing
to note is that service quality is not exclusively and directly tied to the provider's revenue.
Perversion in the system is depicted by the balancing loop, which shows that an organization is
motivated to report what is necessary to get increased funding, which may or may not be related
to service quality. In the diagram, Proclivity to Report Desirable Results refers to reporting
purposes and instead of focusing on program activities. A problem occurs when this balancing
loops is faster and more effective for the provider to increase revenue. Then, doing whatever it
takes to get that report to appear desirable becomes the motivating factor rather than investing in
improving service quality, which is time consuming and may or may not pay off in improving
performance reports.
In addition, if the payer specified performance measures don't include an indicator that
reflects a certain service quality improvement, then the provider is not incentivized to continue
provide that value added service. In other words, payer determined indicators for performance
measures dictate the provider's willingness to improve or change its provided services. In this
second model, patients have little voice in determining the service that they are provided with.
One assumption that must be made for this model to be successful and that is that the
donor's list of performance measures reflect the patient needs. However, it is not clear through
this setup how that feedback occurs. A health care innovation to better improve that
communication can lead to significant impact, especially since this model of the patient not
being the payer will persist in low-income countries with high burden of disease. Dr. Richard
Bohmer of Harvard Business School said, "the most important innovation is organizational-the
creation of organizational structures and processes that foster learning in routine practice and the
creation of more effective models of care delivery" (Bohmer, 2009). Agreeing with his point, I
believe that health care innovation must occur with a systemic lens, understanding that learning
and feedback is extremely important, highlighting the role of M&E within health care
organization.
53 Role of Management Expertise at the Local Level
At the level of the local health care delivery organization, the importance of internal
management becomes ever more important in the midst of the push and pull from external
stakeholders. The challenge of achieving a balance between top down and bottom up priorities
continues to be a struggle for many health care delivery organizations. Analysis of my research
and experience at Kyetume has led me to the following conclusions. In order to stabilize
operational and managerial practices, service providers must strengthen their internal focus by
aligning their strategic plan with M&E practices. The purpose of this is to ensure that
improvements and changes are internally driven.
For instance, the service provider must have a clear and articulated concept of
organizational identity, which includes the scope of care along the care delivery value chain.
Management must consider the cost of expanding to increase the number of services versus
cutting down and focusing on specialization. By identifying the core competencies of the
enterprise, management can analyze whether or not programs are scalable, repeatable, or
transferrable if this is the type of impact the organization hopes to achieve in the future. An
internal driven monitoring and evaluation can then be designed to reflect strategic goals,
measuring progress in a way that allows for continual learning, adaptation, and improvement.
As exemplified at KCBHCP, the application of management practices at the enterprise
level has potential to improve health care delivery. This paper presents data indicators and
processes that currently in place, which can serve as a platform for future analysis of data
organization and management for the purpose of monitoring and evaluation. I am optimistic that
the use business management tools to further study global health practices will lead to significant
benefits in reducing health care inefficiencies and bring about system-wide improvements.
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Appendix A - PEPFAR Next Generation Indicators
Source: PEPFAR Next Generation Indicators Reference Guide (PEPFAR, Aug 2009)
ESSENTIAL/REPORTED INDICATORS Type Sub-type Reporting
Number of pregnant women with known HIV PEPFAR1 status (includes women who were tested for Prevention PMTCT PuPFAR
HIV and received their results) Output
Number of HIV-positive pregnant women PEPFAR2 who received antiretrovirals to reduce risk of Prevention PMTCT Outputmother-to-child-transmission
3 Percent of pregnant women who were tested Prevention PMTCT Nationalfor HIV and know their results. Outcome
Percentage of HIV-positive pregnant women
4 who received antiretrovirals to reduce the Prevention PMTCT National
risk of mother-to-child transmission Outcome
5 Number of known positive pregnant women Prevention PMTCT Output
Number of health facilities providing ANC PEPFAR6 services that provide both HIV testing and Prevention PMTCT PuPFAt
ARVs for PMTCT on site Output
Number of HIV-positive pregnant women
7 assessed for ART eligibility through either Prevention PMTCT PEPFAR
clinical staging (using WHO clinical staging Output
criteria) or CD4 testing
Number of HIV-positive pregnant women PEPFAR8 newly enrolled into HIV care and support Prevention PMTCT Outputservices
9 Percentage of Infants by feeding type Prevention PMTCT PEPFAROutput
10 Percent of infants born to HIV-infected Prevention PMTCT National
mothers who are infected Impact
11 Percentage of donated blood units screened Prevention Blood Safety Nationalfor HIV in a quality assured manner Outcome
Number of units of whole blood collected by
the NBTS network and screened for National
transfusion-transmissible infections per Outcome
1,000 population per year
Proportion of health facilities receiving at
13 least 80% of the blood units used for Prevention Blood Safety Nationaltransfusions from the National Blood Outcome
Transfusion Service network.
14 Percent of blood units collected and screened Prevention Blood Safety Outcome
PEPFAR List of Indicators (continued)
Percentage of health facilities with no stock Injection National15 outs of new sterile syringes (standard or Prevention Safety and Outcome
safety) in the prior 6 months Waste Disposal
Percentage of health facilities with no stock Injection National
16 outs of safety boxes in the prior 6 months Prevention aste dsposal Outcome
Injetio s Ntina
Percentage of health facilities with final Injection National
17 disposal method for health care waste. Prevention aste sposal Outcome
Average number of medical injections per Injection National18 person per year Prevention Safety and OutcomeWaste Disposal
Proportion of women and men age 15-49 Injection
19 reporting that the last health care injection Prevention Safety and National
was given with a syringe and needle set Waste Disposal Outcome
from a new, unopened package
Percent of injecting drug users (IDUs) on Injection and National
20 opioid substitution therapy Prevention Non-injection Outcome
drug use
Number of injecting drug users (IDUs) on Injection and PEPFAR21 opioid substitution therapy Prevention Non-injection Outputdrug use
Number of males circumcised as part of the Male PEPFAR22 minimum package of MC for HIV prevention Prevention Circumcision Output
services
Number of clients circumcised who
23 experienced one or more moderate or Prevention Male PEPFARsevere adverse event(s) within the reporting Circumcision Output
period
Number of locations providing MC surgery as
24 part of the minimum package of MC for HIV Prevention Male PEPFARprevention services within the reporting Circumcision Output
period
Number of males circumcised within the
25 reporting period who return at least once for Prevention Male PEPFARpostoperative follow-up care (routine or Circumcision Output
emergent) within 14 days of surgery
Number of male circumcisions performed Male National26 according to national or international Prevention Circumcision Output
standards, within the reporting period
27 Proportion of males circumcised in the Prevention Male Nationalintended population Circumcision Outcome
28 Number of persons provided with Prevention Post-Exposure PEPFARpost-exposure prophylaxis (PEP) Prophylaxis Output
29 Percentage of health facilities with HIV Prevention Post-Exposure Nationalpost-exposure prophylaxis (PEP) available Prophylaxis Outcome
PEPFAR List of Indicators (continued)
Number of People Living with HIV/AIDS Prevention
30 (PLHIV) reached with a minimum package of Prevention Livn with Output
Prevention with PLHIV (PwP) interventions iv wP
Number of the targeted population reached
with individual and/or small group level Sexualand PEPFAR
31 preventive interventions that are based on Prevention other Risk
evidence and/or meet the minimum standards Prevention
Petrequired
Number of the targeted population reached
with individual and/or small group levele l
32preventive interventions that are primarily Srvnio teua andk PEPFAR
32 reenton other Risk Otu
focused on abstinence and/or being faithful,Prvnin Otu
and are based on evidence and/or meet thePrevention
minimum standards required
Number of MARP reached with individualanex
3 and/or small group level interventions that Prevention other Risk PEPFAR
are based on evidence and/or meet the Prevention Output
minimum standards required
Sexual and PEPFAR
34 Number of targeted condom service outlets Prevention other Risk PEPFAR
Prevention Output
Numoer or inaiviauais from target audience PEPFAR35 who participated in community-wide event Prevention other Risk OutputPrevention
Exposure: % of target population reached: # Sexualand
of people estimated to have been reached, by Se and PEPFAR
channel (radio or TV) divided by the Prevention Output
estimated size of the target population Prevention
Exposure: % of population who recall hearing Sexual and PEPFAR37 or seeing a specific message Prevention other Risk OutputPrevention
Percentage of young women and men aged
15-24 who both correctly identify ways of Sexual and
38 preventing the sexual transmission of HIV and Prevention other Risk National
who reject major misconceptions about HIV Prevention Outcome
transmission
Percent of never-married young people aged Sexual and National
39 15-24 who have never had sex Prevention other Risk OutcomePrevention
Percentage of young women and men aged Sexual and National
40 15-24 who have had sexual intercourse before Prevention other Risk Nationa
the age of 15. Prevention Outcome
Percentage of women and men aged 15-49 Sexual and National
41 who have had sexual intercourse with more Prevention other Risk Nationa
than one partner in the last 12 months Prevention Outcome
PEPFAR List of Indicators (continued)
Percent of women and men aged 15-49 who Sexual and
42 have had more than one sexual partner in the Prevention other Risk Nationallast 12 months reporting the use of a condom Prevention Outcome
their last sexual intercourse.
The percentage of women and men aged Sexual and
43 15-49 with more than one ongoing sexual Prevention other Risk Nationalpartnership at the point in time six months Prevention Outcome
before the interview
Percent of men and women aged 15-49, who Sexual and National44 have two or more concurrent partners within Prevention other Risk Outcomethe past twelve months Prevention
Cross-generational sex: Percentage of
women respondents aged 15-19 who have Sexual and
45 had nonmarital sex with a man 10 years or Prevention other Risk National
more older than themselves in the last 12 Prevention Outcome
months, of all those who have had
non-marital sex in the last 12 months
Sexually active in past year: Percentage of Sexual and National46 young never married people (aged 15-24) Prevention other Risk Outcome
who have had sex in the last 12 months Prevention
Percentage of youth who have ever had Sexual and National
47 sexual intercourse Prevention other Risk OutcomePrevention
Percentage of young people (aged 15-24)
who used a condom the first time they ever Sexual and National48 had sex, of those who have ever had sex, Prevention other Risk Outcomedisaggregated by age group (15-19, 20-24) Prevention
and gender
Percentage of young women and men aged Sexual and National49 15-24 who report they could get condoms on Prevention other Risk Outcometheir own Prevention
Condom use at last premarital sex, last sex:
Percentage of young never married people Sexual and National50 (aged 15-24) who used a condom at last sex, Prevention other Risk Outcome
of all young single sexually active people Prevention
surveyed
Percentage of adults who are in favour of Sexual and National51 young people being educated about the use Prevention other Risk Outcome
of condoms in order to prevent HIV/AIDS Prevention
STIGMA: Percentage of the general Sexual and National52 population with accepting attitudes toward Prevention other Risk OutcomePLHA (UNAIDS) Prevention
Percentage of young women and men aged Sexual and National
15-24 who are HIV infected Prevention other Risk Impact
__________Prevention Ipc
PEPFAR List of Indicators (continued)
Percentage of most-at-risk populations who
54 both correctly identify ways of preventing the Concentrated National
sexual transmission of HIV and who reject Prevention Epidemics Outcome
major misconceptions about HIV transmission
Percentage of female and male sex workers Concentrated National
55 reporting the use of a condom with their most Prevention Epidemics Outcome
recent client
Percent of men aged 15-49 reporting sex Concentrated National
56 with a sex worker in the last 12 months who Prevention Epidemics Outcome
used a condom during last paid intercourse
Percentage of men reporting the use of a Concentrated National
57 condom the last time they had anal sex with Prevention Epidemics Outcome
a male partner
Percentage of injecting drug users reporting Concentrated National
58 the use of a condom the last time they had Prevention Epidemics Outcome
sexual intercourse
Percentage of injecting drug users reporting Concentrated National
59 the use of sterile injecting equipment the last Prevention Epidemics Outcome
time they injected EpidemicsOutcome
Percent of male respondents aged 15-49 - Concentrated National
60 reporting sex with a sex worker Prevention Epidemics Outcome
Percentage of female and male sex worker Concentrated National61 reporting the use of a condom with every Prevention Epidemics Outcome
client in the last month
Percentage of men who have had anal sex
62 with more than one male partner in the last 6 Prevention Concentrated Nationalmonths of all men surveyed who have sex Epidemics Outcome
with a male partner
Percentage of most-at-risk populations (IDU, Concentrated National
63 MSM, SW) who received an HIV test in the Prevention Epidemics Outcome
last 12 months and who know the results
Percentage of IDU active in the last month Concentrated National
64 who report sharing injecting equipment the Prevention Epidemics Outcome
last time they injected drugs
65 Percentage IDU who sought treatment for Prevention Concentrated NationalSTI, of those reporting symptoms Epidemics Outcome
Percentage of IDUs surveyed who used a Concentrated National
66 condom the last time they had sex with a Prevention Epidemics Outcome
regular partner
Percentage of IDUs surveyed who used a Concentrated National
67 condom the last time they had sex with a Prevention Epidemics Outcome
nonregular partner
Percentage of military personnel reporting Concentrated National68 more than one sexual partner in the past 12 Prevention Epidemics Outcome
months
PEPFAR List of Indicators (continued)
Percentage of military personnel who received Concentrated National69 HIV test in the past 12 months and know Prevention Epidemics Outcome
their results
70 Percentage of most-at-risk populations (IDU, Prevention Concentrated NationalMSM, SW) who are HIV-infected Epidemics Outcome
Number of enterprises implementing an Work Place PEPFAR71 HIV/AIDS workplace program, providing at Prevention Programs Outputleast one of the 4 critical components
72 Estimated number of people reached through Prevention Work Place PEPFAR
work place programs Programs Output
Percent of large enterprises/companies that Work Place National
73 have HIV/AIDS workplace policies and Prevention Programs Outcomeprograms
Number of individuals who received Testing Testing and PEPFAR74 and Counseling (T&C) services for HIV and Prevention Counseling Output
received their test results
Percentage of women and men aged 15-49 Testing and National
75 who received an HIV test in the last 12 Prevention Counseling Outcome
months and who know their results
76 Percentage of health facilities that provide Prevention Testing and NationalHIV testing and counselling services Counseling Outcome
Percent of districts that provide HIV Testing Prevention Testing and National
and Counseling services Counseling Outcome
Percentage of HIV Testing and Counseling
78 sites with Quality Assurance (QA) systems for Prevention Testing and NationalHIV counseling service delivery (non-test Counseling Outcome
elements).
Percentage of the patient population aged 15
and older who received HIV T&C and received Prevention Testing and National
their results through provider-initiated Counseling Outcome
services in the past 12 months
Population of people with a sexually
transmitted infection (STI) aged 15 and older Testing and National80 who received HIV T&C and received their Prevention Counseling Outcome
results through provider-initiated services in
the past 12 months
81 Percentage of HIV positive individuals who Prevention Testing and Nationalknow their status Counseling Outcome
Male Norms and Behaviors: Number of people
reached by an individual, small-group, or PEPFAR82 community-level intervention or service that Prevention Gender Output
explicitly addresses norms about masculinity
related to HIV/AIDS
PEPFAR List of Indicators (continued)
Gender Based Violence and Coercion: Number
of people reached by an individual, small
83 group or community-level intervention or PEPFAR
service that explicitly addresses Prevention Gender Output
gender-based violence and coercion related
to HIV/AIDS
Women's Legal Rights and Protection:
Number of people reached by an individual,
84 smallgroup, or community-level intervention Prevention Gender PEPFAR
or service that explicitly addresses the legal Output
rights and protection of women and girls
impacted by HIV/AIDS
Number of people reached by an individual,
small group, or community-level intervention PEPFAR85 or service that explicitly aims to increase Prevention Gender Outputaccess to income and productive resources of
women and girls impacted by HIV/AIDS
Number of eligible adults and children Umbrella PEPFAR
86 provided with a minimum of one care service Care Care Output
_______________________________________Indicators O tu
Number of eligible adults and children Umbrella National87 provided with a minimum of one care service Care Care Output
Number of HIV-positive adults and children PEPFAR
88 receiving a minimum of one clinical service Care Clinical Care Output
89 Number of HIV-positive persons receiving Care Clinical Care PEPFAR
cotrimoxazole prophylaxis Output
Number of HIV-positive clinically PEPFAR
90 malnourished clients who received Care Clinical Care Output
therapeutic or supplementary food
TB/HIV: Percent of HIV-positive patients who
91 were screened for TB in HIV care or Care Clinical Care PEPFAR
treatment settings Output
TB/HIV:Percent of HIV-positive patients in
92 HIV care or treatment (pre-ART or ART) who Care Clinical Care Output
started TB treatment
TB/HIV: Number of eligible HIV positive
93 patients starting Isoniazid Preventive Therapy Care Clinical Care PEPFAR
(IPT) Output
94 Percent of ART sites that have pain Care Clinical Care National
management programs Outcome
Percent of health care facilities that have the
95 capacity and conditions to provide advanced Care Clinical Care Nationallevel HIV/AIDS care and support services, Outcome
including provision of ART
PEPFAR List of Indicators (continued)
Percent of health care facilities that have
96 the capacity and conditions to provide Care Clinical Care Nationalbasic-level HIV testing and HIV/AIDS Outcome
clinical management
97 Percent of HIV-positive patients who are Care Clinical Care Nationalgiven cotrimoxazole preventive therapy Outcome
98 Quality of life for People Living with Care Clinical Care National
HIV/AIDS (PLHIV) Impact
Number of TB patients who had an HIV Clinical/Preventive PEPFAR
99 test result recorded in the TB register Care einal TB/HIV Output
Percent of TB patients who had an HIV Clinical/Preventive National
100 test result recorded in the TB register are dional TB/HIV Outcome
Percent of estimated HIV-positive Clinical/Preventive National101 incident TB cases that received treatment Care Services - Outcomefor TB and HIV Additional TB/HIV
Percent of HIV-positive patients who Clinical/Preventive National102 were screened for TB in HIV care or Care Services - Outcometreatment settings Additional TB/HIV
Percent of infants born to HIV-positive Clinical/Preventive
103 women who received an HIV test within Care Srvices - PEPFAR
12 months of birth Additional OutputPediatric
Percent of infants born to HIV-positive Clinical/Preventive PEPFAR
104 pregnant women who are started on CTX Care Services - Outcome,
prophylaxis within two months of birth Additioal Nationale
Percent of health facilities that provide Clinical/Preventive
105 virological testing services for infant Care Services - Nationaldiagnosis for HIV exposed infants, on site Additional Outcome
or through Dried Blood Spots (DBS). Pediatric
106 Number of eligible clients who received Care Support Care PEPFARfood and/or other nutrition services Output
107 Number of eligible children provided with Care Support Care PEPFARshelter and care-giving Output
108 Number of eligible children provided with Care Support Care PEPFARhealth care referral Output
109 Number of eligible children provided with Care Support Care PEPFAR
Education and/or vocational training Output
Number of eligible adults and children PEPFAR110 provided with Protection and Legal Aid Care Support Care Output
services
PEPFAR List of Indicators (continued)
Number of eligible adults and children PEPFAR
111 provided with psychological, social, or Care Support Care Output
spiritual support Output
Number of eligible adults and children PEPFAR
112 provided with Economic Strengthening Care Support Care Output
services
Percentage of orphaned and vulnerable
113 children aged 0-17 whose households Care Support Care National
received free basic external support in Outcome
caring for the child
114 Quality of life for OVC Care Support Care NationalImpact
Number of adults and children with PEPFAR
115 advanced HIV infection newly enrolled on Treatment ARV Services Output
ART Output
Number of adults and children with PEPFAR
116 advanced HIV infection receiving Treatment ARV Services Output
antiretroviral therapy (ART) [CURRENT]
Percent of adults and children known to be PEPFAR
117 alive and on treatment 12 months after Treatment ARV Services Outcome
initiation of antiretroviral therapy Outcome
Number of adults and children with
118 advanced HIV-infection who ever started on Treatment ARV Services P
ART W "". I II
119 Number of health facilities that offer ART Treatment ARV Services PEPFAR
Outcome
120 Percent of adults and children with advanced Treatment ARV Services NationalHIV infection receiving antiretroviral therapy Outcome
121 Percentage of health facilities that offer ART Treatment ARV Services National
Outcome
Percentage of health facilities providing ART National
122 using CD4 monitoring in line with national Treatment ARV Services Outcome
guidelines/policies on site or through referral
Number of testing facilities (laboratories) Health PEPFAR
123 with capacity to perform clinical laboratory System Laboratory Output
tests Strengthening
Percent of testing facilities (laboratories) Health PEPFAR
124 that are accredited according to national or System Laboratory Outcome
international standards Strengthening Outcome
Percent of laboratories with satisfactory Health
125 performance in external quality System Laboratory National
assurance/proficiency testing (EQA/PT) Strengthening Outcome
program for CD4 (patient monitoring).
Percent of HIV rapid test facilities with
satisfactory performance in external quality Health National
126 assurance/proficiency testing (EQA/PT) System Laboratory Outcome
program for HIV rapid test (HIV Strengthening
diagnostics).
PEPFAR List of Indicators (continued)
Percent of laboratories with satisfactory
performance in external quality Health National127 assurance/proficiency testing (EQA/PT) System Laboratory Outcomeprogram for AFB smear microscopy (TB Strengthening
Diagnostics).
Percent of designated laboratories with the Health
128 capacity to monitor antiretroviral System Laboratory Nationalcombination therapy according to national Strengthening Outcome
and international guidelines
Number of new health care workers who Health Human PEPFAR129 graduated from a pre-service training System Resources Outputinstitution Strengthening for Health
Number of community health and Health Human PEPFAR130 para-social workers who successfully System Resources Output
completed a pre-service training program Strengthening for Health
Number of health care workers who Health Human PEPFAR131 successfully completed an in-service System Resources Outputtraining program Strengthening for Health
Number of new health care workers who Health Human National132 graduated from a pre-service training System Resources Outputinstitution Strengthening for Health
Health Human National
133 Ratio of health workers to 10,000 population System Resources OutputStrengthening for Health
Domestic and international AIDS Spending Health Health National134 by categories of financial sources (NASA or System Systems OutcomeNHA) Strengthening Financing
Health Health National135 Total health expenditures per capita System Systems OutcomeStrengthening Financing
Health Service National
136 Proportion of all deaths attributable to HIV System Delivery Impact
Strengthening
Ratio between the median price paid by the Health Medical National137 country for each ARV in the last 12 months System Products, etc Outputto the median international price Strengthening
Proportion of generic to branded drugs Health Medical National138 procured Ste Products, etc Outcome
Percentage of health facilities providing ART Health Medical National139 that experienced stock-outs of ARV in the System Products, etc Outcome
last 12 months Strengthening
Monitoring policy reform and development Health Health PEPFAR140 of PEPFAR supported activities (Required for System Systems OutcomePartnership Framework Countries) Strengthening Governance
PEPFAR List of Indicators (continued)
Health Health National
141 National Composite Policy Index (NCPI) System Systems Nationa
Strengthening Governance Outcome
Existence of national costed HIV Health Health National142 implementation plan System Systems OutcomeStrengthening Governance
Existence of effective civil society Health Health National143 organizations System Systems OutcomeStrengthening Governance
National Human Resource Information Health Health National144 System in place with key elements System Information OutcomeStrengthening Systems
Existence of one agreed upon M&E plan for Health Health National145 overall national monitoring and evaluation System Information Outcome
. Strengthening Systems
Percent of health facilities with Health Health National
146 record-keeping systems for monitoring System Information Outcome
HIV/AIDS care and support Strengthening Systems
Percent of ARV distribution nodes that Health Health National
147 report on inventory consumption, quality, System Information Outcome
losses, and adjustments on a monthly basis Strengthening Systems
Existence of a national and sub-national
HAII-hncac thnf iannha testakeholdersto IIIhHatWxJ 1W %-I'. ~a I II L;U II INational148 access relevant data for policy formulation System Information Outcome
and program management and Strengthening Systems
improvement
Existence of a designated and functioning
institutional mechanism charged with Health Health
149 analysis of health statistics, synthesis of System Information National
data from different sources and validation of Strengthening Systems Outcome
data from population and facility sources
Availability of HIV prevalence data for Health Health National
150 relevant surveillance populations published System Information Outcome
within 12 months of preceding year Strengthening Systems
Existence of a nationally coordinated
multi-year disease Monitoring and Health Health National
151 Evaluation plan with a schedule for survey System Information Outcome
implementation and data analysis prepared Strengthening Systems
and implemented
Health Health National
152 Availability of maternal mortality data System Information Outcome
Strengthening Systems Outcome
Health Health National
153 Availability of child mortality data System Information Outcome
Strengthening Systems Outcome
Appendix B - PEPFAR Uganda Program Results
Source: www.pepfar.gov (The US President's Emergency Plan For AIDS Relief, 2011)
Uganda Program Results
Indicators
Pregnant women receiving HIV testing
and counseling services*
Number of HIV+ pregnant women
receiving ARV prophylaxis*
Number of individuals reached with
community outreach HIV/AIDS
prevention activities that promote
abstinence and/or being faithful
Number of individuals reached with
community outreach HIV/AIDS
prevention activities that promote
correct and consistent use of
condoms and related interventions
Total number of individuals reached
(on ART)*
Progress Toward Emergency Plan
Target of 10 Million Individuals
Receiving Care*
Orphans and Vulnerable Children
Results*
Testing & Counseling Services
Results (in settings other than
PMTCT)*
Number of individuals who received
care & support (including TB/HIV)*
Number of individuals who received
care & support services that are
receiving treatment for TB disease
(subset of all care & support)*
FY2005 FY2006
250,000
11,300
FY2007
300,000
14,700
565,100
29,800
FY2008
830,000
41,600
3,639,200 5,654,800 7,165,400 4,519,800
3,606,400 1,651,300 1,001,100 1,737,000
67,500
371,200
93,600
89,200
511,800
221,900
106,000 145,000
722,300 1,146,100
307,800 754,000
1,099,300 1,000,000 1,490,900 2,043,400
258,900
18,800
289,900
21,200
414,500
16,400
392,100
14,400
Appendix C - The Global Fund Top Ten Indicators
Source: Top Ten Indicators Card, Monitoring and Evaluation Guidelines and Tools (The
Global Fund to Fight AIDS, Tuberculosis, and Malaria, 2010)
A. Top Ten Indicators for Routine Global Fund Reporting
Disease Indicators for routine Global Fund reporting
1 HIV Number of adults and children with advanced HIV infection currently
receiving antiretroviral therapy
2 TB Number of (a) new smear-positive TB patients detected, (b) new smear-
positive TB patients who were successfully treated and (c) laboratory-
confirmed MDR-TB patients enrolled in second-line anti-TB treatment
3 Malaria Number of (a) insecticide-treated nets or re-treatment kits distributed to
people and (b) households (or structures or walls) in designated target areas
sprayed by indoor residual spraying in the past 12 months
4 Malaria Number of people with fever receiving antimalarial treatment according to
national policy (specify artemisinin-based combination therapy versus other
therapy)
5 HIV Number of women and men aged 15-49 years who received an HIV test in the
last 12 months and who know their results
6 HIV Number of HIV-positive pregnant women who received antiretrovirals to
reduce the risk of mother-to-child transmission
7 HIV Number of condoms distributed
8 HIV, TB and malaria Number of people benefiting from community-based programs: specify (a)
care and support including orphan support, home-based management of
malaria and directly observed therapy (DOT); (b) behavior change
communication outreach activities including specific target groups; and (c)
disease prevention for people most at risk (except behavior change
communication)
9 1 HIVITB Number of TB patients who had an HIV test result recorded in the TB register
10 1 Strengthening health systems for HIV, TB and malaria Number of people trained
B. Top Ten Indicators for Medium-Term Outcome and Impact
Disease Indicators recommended for generalized epidemics indicators recommended for concentrated
and high-endemicity areas epidemics and low-endemicity areas
1 HIV Percentage of women and men aged 15-24 years wvho Percentage of populations most at risk who are
are infected with HIV infected with HIV
2 HIV Percentage of adults and children with HIV known to be receiving treatment 12 months after initiation of
antiretroviral therapy (extend to two, three and five years as the program matures)
3 HIV Reduced mother-to-child transmission of HIV:
percentage of infants bom to mothers who are HIV
infected
4 HIV Percentage of people aged 15-49 years with more than Percentage of populations most at risk with more than
one sexual partner in the past 12 months reporting the one sexual partner in the past 12 months reporting
use of condoms during their last sexual intercourse the use of condoms during last sexual intercourse
5 TB TB case detection rate and treatment success rate
6 TB TB prevalence rate: estimated number of TB cases (all forms) per 100 000 population
7 Malaria All-cause mortality rate among children younger than Malaria-specific mortality: proportion of deaths
five years of age attributed to malaria among children younger than
five years of age (or other target groups)
8 Malaria Number of (confirmed) malaria cases seen by health a. Annual parasite index
workrs in fciltiesandor otrech)b. Slide-positive or rapid diagnostic test-positive rate
9 Malaria People sleeping under an insecticide-treated net the previous night (specify the target population: all
household residents, children younger than five years of age, pregnant women)
10 Health systems All-cause mortality rate among children younger than five years of age
strengthening
Appendix D - MAP Scorecard
Source: The Africa Multi-Country AIDS Program 2000-2006: Results of the World Bank's
Response to a Development Crisis (World Bank, 2007)
2. Estimated number of Number UNAIDS UNAIDS Global Report
adults and children living
with HIV
3b. Sex workers in the capi- Percentage
tal city who are living
with HIV
4a. Condom use; Men and
women aged 15-49
reporting the use of a
condom during last sex-
ual intercourse (of those
reporting sexual inter-
course in the last
12 months)
Percentage
UNGASS
alternate
indicator
UNGASS
UNAIDS Global Report,
WHO estimates
ISR f"s**"m LN*U" mWS
5. Women and men aged Percentage UNGASS SNCASR nSiw
15-24 who have had sex
with more than one part-
ner in the last 12 months
MAP Scorecard (continued)
Orphans and vulnerable Number UNGASS 1SR awomrvouwAm ewe
children whose house-
holds have received Percentage SR " ""n A*W*
carefsupport in the past
12 months
10. Male andfornale con- Number World Bank ISR wwI
doms distributed I I I
12. Public setor organiza- Number Word Bank 5
tions supportedI
Amount of tSR OW
funding
MAP Scorecard (continued)
Isa. Counry commkments I Amount | World Bank I ISR " m en ^ n*. I
15c. Other development Amount J World Bank | Development partner
parners' commitment j Web sites
17. World Bank financial
disbursements for HIV,
UsS
Amount World Bank World Bank Client
Connection
Note: All of the indicators in the scorecard are based on the latest international consensus on indica-
tor wording. As there are currently efforts under way to harmonize indicators, the indicators in the
scorecard may be slightly revised in 2008, when the harmonization process will be complete.
Scorecard data are not disaggregated into age groups or sex. This will be reviewed in the future as
better data sets become available.
mmi
Appendix E - UNGASS Core Indicators for the Implementation of the
Declaration of Commitment on HIV/AIDS
Source: UNGASS Guidelines on Construction of Core Indicators for 2010 Reporting
(UNGASS, March 2009)
Data Colection
Frequency
Method of Data
Collection
Expenditures
1. Domestic and international ADS spending by categories and financing Ad hoc based on Naional AIDS Spending
sources country request and Assessment
financing, by calendar Financial resource Rows
or fiscalyear
Policy Development and Implementation Status
2. National Composite Policy Index (Areas covered: prevention, treatment Every 2 years Desk review and key
care and support, human rghts, vi society involvemert, gender, informant interviews
worklcace prograrmes, stigma and discriminaton and monitoring and
evaluation)
National Programmes (blood safety, antiretrovral therapy coverage, prevention of mother-to-child
transmission, co-management of TB and HIV treatment, HPV testing, prevention programmes, services for
orphans and vulnerable children, and education)
3. Pernage of donated blood units screened for HW in a quaity assured Annual Programme monrpadng/
manner special survey
4. Percentage of adults and children with advanced HWinfection receiving Annual Programme monitoring
antiretroviral therapy* and estimates
5. Percentage of HN-positive pregnant women who receive antretroviral Annual Programme montoring
medicines to reduce the risk of mothertov-child transmission and estimates
6. Percentage of estimated HN-positive incident TB cases that received Annual Programme monitoring
treatment for TB and HO
7. Percemage of women and men aged 15-49 who received an HN test in Every 4-5 years Popuwatiobased survey
the last 12 months and who know the mt
S. Percentage of most-at-risk populations that have received an HW test in Every 2 years Behavioural surveys
the last 12 rmonths and who know the results
9. Percentage of most-a:-risk populations reached with HN orevention Every 2 yes Behavioural surveys
programmes
10. Percentage of orphans and vulnerable chaldren whose households Every 4-5 years Population-based survey
received free basic external support in caring for the chid
i. Percentage of schools that orovided life skills-based NV education Every 2 years Schoosbased survey
within the last academic year
Indicators
UNGASS Core Indicators (continued)
Indicators Data Collection Method of Data
Frequency Collection
Knowledge and Behaviour
12. Current school atendance among orphans and aon.g non-orphans Every 4-5 years PopUlasion-based survey
aged 10-14*
11 Peternage o young women and men aged15-24 who both coreOdy Every 4-5 years Population-based survey
ideni fy ways of preven ing the sexual transmtssn of HW and who
reject major risconceptions about NW trarsmission*
14. Percentage of most-at-rsk cooulations who both corecty dentiy Every 2 years Behavioural surveys
ways of preventing te sexual transmission of HIV and who reject major
misconceptions about HIV transmission
15. Percentage of young women and men who have had sexual Intercourse Every 4-5 years Popu a onbased survey
before the age of 15
16. Percertage of adults aged 15-49 who have had sexual intercoursewth Every 4-5 years Populaton-based survey
more than one partner in the last 12 months
17. Percentage of adults aoed 1549 who had more than one sexual partner Every 4-5 years Populatsobased survey
in the past '2 months who report the use of a condom during their ast
intercourse'
"S, Percertage of ferae and male sex w cters reporting the use of a Every? yeas Behavioural surveys
condor with tneir most recent client
9. Percentage of en reportirg the se of a condom the last rne they Every 2 years Behavioural surveys
hac anal sex wSth a mae artner
21. Percentage o jectir'g drg users who -eponed the use of a condom Every 2 years Special survey
at last sexua intercourse
21 Percentage of injecting drug users who reported using sterile injectng Every 2 yeas Spc0ial survey
ecuipment the last time they injected
Impact
22 Percentage of young womer and men aged 5-24 who are V Annual NV sentinel surve Alance
iriected' and populaion-based
survey
21 Percentage of rost-at-rsk populations who are HN infected Annual HN sentinel surveillance
24. Percentage of adults and chidren wth HN knoan to be on treatment Every 2 years Programme monitorng
12months after initiation of arntretrcviral therapy
25. Percentage of znfants bom to HA infected mothers who are infected A-r-al Treatment protocols and
efficacy studies
Appendix F - WHO Core National M&E indicators
Source: National AIDS Programmes: A Guide to Monitoring and
and Support (WHO, March 2004)
Evaluating HIV/AIDS Care
Core indicators
CS1 Percentage of the general population aged 15-49 years receiving HIV
test results and post-test counselling in the past 12 months
CS2 Percentage of districts with at least one health facility providing antiretroviral
combination therapy
CS3 Percentage of people with advanced HIV Infection receMng antiretroviral
combination therapy'
CS4 Existence of comprehensive HIV/AIDS care and support policies,
strategies and guidelines
CS5 Percentage of facilities that provide comprehensive care referrals
for IV/AIDS care and support services (when these services are
not available on site)
CS6 Percentage of health faclities that have the capacity and conditions
to provide basic HIV counseling and testing and to manage HN/AIDS
clinical services
(a) A system for testing and providing results for HIV infection
(b) Systems and qualified staff for pre- and post-test counselling
(C) Speciflc health services relevant to HIV/AIDS, inciidinn reotirces and
supplies for providing these services
(d) Elements for preventing nosocomial Infections
(e) Trained staff and resources providing basic interventions for prevention
and treatment for people living with IV/AIDS
CS7 Percentage of health facilities that have the capacity and conditions
to provide advanced HIV/AIDS clinical and psychosocial support services,
including providing and monitoring antiretroviral combination therapy
(a) Systems and items to support the management of opportunistic
Infections and the provision of palliative care (symptomatic treatment)
for the advanced care of people lMng with HNi/AIDS;
(b) Systems and items to support advanced services for the care
of people living with HIV/AIDS
(c) Systems and items to support antiretroviral combination therapy
(d Conditions to orovide advanced innatient care for newole ino
Recommended
method
Programme reports
Programme reports
Programme reports
and modelling
Interviews and
record review
Health facility survey
Health facility survey
Health faclity survey
Frequency
Annual
Annual
Every 2 years
Every 2 years
Every 2-4 years
Every 2-4 years
Every 2-4 years
WHO Core National M&E Indicators (continued)
(d) Conditions to provide advanced Inpatient care for people living
with HN/AIDS(e) Conditions to support home care services
( Postexposure prophylaxis
CS8 Percentage of designated laboratories with the capacity to monitor
antiretroviral combination therapy according to national and International
guidelines
CS9 Percentage of adults aged 18-59 years who have been chronically iII
for 3 or more months In the past 12 months whose households received,
free of user charges, basic external support in caring for chronically 1ll
adults, Including health, psychological or emotional and other social
and material support
CS10 Percentage of orphans and vulnerable children whose households received,
free of user charges, basic extemal support In caring for the child
Health facility survey
or special laboratory
study
Household survey
Household survey
To be determined
Every 2-4 years
Every 2-4 years
Additional indicators Method Frequency
CS-Al Existence of national monitoring and evaluation capacity for HIVADS Interview or record Every 2 years
care and support programmes reviews
CS-A2 Percentage of health facilities wth record-keeping systems Health facility survey Every 2-4 years
for monitoring HIV/AIDS care and support
Monitoring the Declamtion of Commitment on HIV/AIDS: guidelines on constmction of core indicators. Geneva. UNAIDS.
2002 (http:/.h\ unaids.org/html/pubPublications/IRC-pubO2/JC894-Coreindicators en-pdf.htm. accessed I October 2003).
Appendix G - KCBHCP, IRCU Indicators
Source: KCBHCP, MIT GHD Lab Team, accessed on site
A. Filled Daily, Per Patient - Feeds into IRCU 2a Monthly Report
Demographic information
1. Sex M F 2. If female, pregnant?
3.Age
4. Marital status Single / Married / Widowed / Divorced / SeParated / Co
5. # of biological children age<15 yrs 6. Out of which tested for HIV
7. Out of which HIV+ )
8. Client's school status S (at school) 0 (out school)
HCT: In this visit, was the client:
9. Counselled for HIV? VY N 10. Tested for H IV?
11. First time tester? Y / N 12. Given HIV test results?
13. Client HIV status (regardless of whether tested here)
HCT: During this visit, was the client's partner:
14. Tested and counselled? Y / N 15. If tested, HIV status?
Family planning & Palliative care: During this visit, has the client received:
16. Counselling for family planning? Y / N 17. Family planning service?
18 Already using family planning? Y / N 19. Nutrition support?
20. Cultural ly-appropriate end-of-life care?
21. Insecticide treated nets (ITN)? Y / N 22. Education on use of safe water?
23. Spiritual support? Y / N 24. Psychological care?
25. Clinical monitoring and management of opportunistic infections?
26. Reported that s/he is accessing home-based care?
27. Been given a home-based care kit?
PMTCT: If a female client has a child of age <1, in this visit:
28. Does the client have a child less than 1 year?
29. If yes, has the child been tested for HIV?
30. The child's HIV status is
31. if the child is positive, has s/he received prophylaxis?
PMTCT: If a female client is pregnant, in this visit:
32. Has she been counselled, tested, and received results for PMTCT?
33. Has she received a complete course of antiretroviral prophylaxis in a PMTCT setting?
Clinical care and ART
34. Client's weight ( ) 35. WHO clinical stage
36. Latest CD4 count (cells/mm3) ( ) 37. On Cotrimoxazole in this visit?
38. Receiving pain management in this visit?
39. Screened for ART? What date?
40. Put on ART waiting list in this visit?
TB
41. Assessed for TB in this visit?
42. If assessed for TB, result is:
43. Newly registered for TB treatment in this visit?
44. If not, is the client being given TB treatment in this visit?
45. Completed/finished TB treatment in this visit?
STI
46. Screened/tested for STIs in this visit?
47. If yes, what is the client status?
48. Received treatment for the STI in this visit?
Other HIV-related questions
49. Counselled and received medical make circumcision in this visit?
50. Referred in for the HIV/AIDS services?
51. Referred out for the HIV/AIDS services?
Y / N
habiting
Y N
Y /N
P/N
P / NA
Y/
Y/
Y/
Y/
y
y/
Y/
Y /N
Y /N
P /N
Y /N
Y /N
V/N
Y /N
I/I / IV
Y N
Y /N
Y /N
C (case) /S (suspect)
Y /N
Y /N
Y /N
Y / N
P (positive) / N (negative)
Y /N
Y /N
Y /N
Y /N
B. Monthly VCT Form - Feeds into IRCU 2a
No. Data element
Care/Support - VCT
1
21Counseled 0 - 4 years - male
2
Counseled 0 -4 years - female
3
41Counseled 5 -14 years - male4
Counseled 5 -14 years - female
5
Counseled 15 -24 years - male
6
Counseled 15 -24 years - female
7
Counseled 25 -49 years - male
8
Counseled 25 -49 years -~ female
9
Counseled 50 years and above - male
10
15
HIV tested on static site 0 4 years - male
NubeIcet testedg onr sttcste fi4yrsim - male
15
NubeIcet testedg onr sttcste istm -14ers-male
16
HIV tested on static site 5 - 4 years - male
17
HIV tested on static site 15 -4 years - fmale
18
HIV tested on static site 15 -24 years -fmale
19
HIV tested on static site 25 -49 years - male
20
HIV tested on static site 25 -49 years - female
Monthly VCT Form - Feeds into IRCU 2a (continued)
21
HIV tested on static site 50 and above years - male
22
HIV tested on static site 50 and above years - female
23
HIV tested in outreach 0 - 4 years - male
24
HIV tested in outreach 0 - 4 years - female
25
HIV tested in outreach 5 - 14 years - male
26
HIV tested in outreach 5 - 14 years - female
27
HIV tested in outreach 15 -24 years - male
28
HIV tested in outreach 15 -24 years - female
29
HIV tested in outreach 25 -49 years - male
30
HIV tested in outreach 25 -49 years - female
31
HIV tested in outreach 50 and above years - male
32
HIV tested in outreach 50 and above years - female
33 HIV positive 0-4 years - male
34 HIV positive 0-4 years - female
35 HIV positive 5-14 years - male
36 HIV positive 5-14 years - female
37 HIV positive 15 -24 years - male
38 HIV positive 15 -24 years - female
39 HIV positive 25 -49 years - male
40 HIV positive 25 -49 years - female
41 HIV positive 50 and above years - male
42 HIV positive 50 and above years - female
43 HIV positive referred 0-4 years - male
44 HIV positive referred 0-4 years - female
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Family planning (FP) - Condom distribution
viontm V I rorm - r ees into iKUu za Lcontmfueaj
45 HIV positive referred 5-14 years - male
46 HIV positive referred 5-14 years - female
47 HIV positive referred 15 -24 years - male
48 HIV positive referred 15 -24 years - female
49 HIV positive referred 25 -49 years - male
50 HIV positive referred 25 -49 years - female
51 HIV positive referred 50 and above years - male
52 HIV positive referred 50 and above years - female
Care/Support - Community mobilization
53 Out reaches condcted
Care/Support - PLWHA
54 PLWHA on register - male
55 PLWHA on register - female
56 PLWHA provided with home Based Care - male
57 PLWHA provided with home Based Care - female
58 Total number of visits made
59 PLWHA provided with Medical Care Assistance - male
60 PLWHA provided with Medical Care Assistance - female
61 PLWHA provided with Insecticide Treated Nets - male
62 PLWHA provided with Insecticide Treated Nets - female
Appendix H - KCBHCP Full List of Indicators
Source: KCBHCP, MIT GHD Lab Team, accessed on site
1 No. of HCT outreaches
2 No. of clients home visited
3 No. of clients counseled
4 No. of clients testing for the first time
5 No. of HIV tests carried out
6 No. of HIV tested on static site
7 No. of HIV tested in outreach
8 No. of HIV tests carried out test positive
9 No. of HIV tested during outreach (from lab register) positive
10 No. of HIV tested on static (from lab register) positive
No. of clients counseled, tested & received results (including
11 TB/HCT)
12 No. of HIV (+) referred
13 No. of AIDS diagnoses
14 No. of HIV testing kits - Confirmatory
15 No. of HIV testing kits - Screening
16 No. of HIV testing kits - Tie-breaker
17 No. of other non - occupation
18 No. of other outreaches
19 Type of Service Outlet
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21 No. of female sterilisation (tibal ligation)
22 No. of implant new users
23 No. of implant removals
24 No. of implant revisits
25 No. of injectable contraceptives dispensed
26 No. of injectable FP users
27 No. of IUDs (Copper T) contraceptives dispensed
28 No. of IUDs (Copper T) FP users
29 No. of male sterilisation (vasectomy)
30 No. of males circumcised
31 No. of males reviewed after two weeks of procedure
No. of males reviewed during two weeks of procedure and
32 developed complications
33 No. of natural FP users
34 No. of oral: Lo-Femenal contraceptives dispensed
35 No. of oral: Lo-Femenal FP users
36 No. of oral: Microgynon contraceptives dispensed
37 No. of oral: Microgynon FP users
38 No. of oral: Others contraceptives dispensed
39 No. of oral: Others FP users
40 No. of oral: Ovrette contraceptives dispensed
41 No. of oral: Ovrette FP users
42 No. of other methods FP users
43 No. of others contraceptives dispensed
44 No. of rape/sexual assault victim cases
45 No. of total family planning users
46 No. of clients referred
47 No. of PHA in care eligible for ART
48 No. of clients EVER enrolled
49 No. of clients on ARVs
50 No. of new clients enrolled on ARVs
51 No. of old clients visiting for ART refills
52 No. of ART clients who are severely malnourished
No. of severely malnourished ART clients who received
53 food/nutritional supplementation
54 No. of PLWHA on register
55 No. of clients with HIV attended to at OPD
56 No. of PLWHA provided with home Based Care
57 No. of PLWHA provided with Insecticide Treated Nets
58 No. of PLWHA provided with Medical Care Assistance
59 No. of visits made
60 No. of home visited clients
61 No. of Community counseling Aidees (CCA) trained
62 No. of new clients on septrine
63 No. of old clients on septrine
64 No. of clients on septrine
No. of HIV (+) patients in HIV care or treatment (pre-ART or ART)
65 who started TB treatment and are lost to follow up
No. of HIV (+) patients in HIV care or treatment (pre-ART or ART)
66 who were tested for TB
No. of HIV (+) patients in HIV care or treatment (pre-ART or ART)
67 who were referred and diagnosed for TB
No. of HIV (+) patients in HIV care or treatment (pre-ART or ART)
68 who started TB treatment
No. of HIV (+) patients in HIV care or treatment (pre-ART or ART)
69 who started TB treatment and are followed up for CB-DOTS
No. of HIV (+) patients in HIV care or treatment (pre-ART or ART)
70 who cured on DOTS (Directly Observed Treatment, Short course)
No. of HIV (+) patients in HIV care or treatment (pre-ART or ART)
71 who started TB treatment and died
72 No. of HIV (+) clients tested for STI
73 No. of HIV clients tested positive and treated for STI
74 No. of HIV (+) persons in care and died
75 No. of persons provided with PEP (please indicate their occupation)
76 No. of anemia cases
77 No. of asthma cases
78 No. of candidiasis cases
79 No. of carbanculosis cases
80 No. of clients referred for sputum analysis
81 No. of TB sputum tests
82 No. of TB sputum tests positive
83 No. of tuberculosis cases
84 No. of TB clients counseled, tested and received for TB
85 No. of Cotrimoxazole tabs administered
86 No. of Depo-Provera administered
87 No. of depression cases
88 No. of diarrhea - acute cases
89 No. of diarrhea - persistent cases
90 No. of dysentery cases
91 No. of ENT Conditions cases
92 No. of EPI (Expanded Program of Immunization) outreaches
93 No. of eye conditions cases
94 No. of Fansidar
95 No. of first line drug for Malaria*
96 No. of fungal infection cases
97 No. of H.C.G tests
98 No. of H.C.G tests positive
99 No. of HIV (-) patients on TB treatment
100 No. of new clients on TB drugs
No. of HIV (-) patients in HIV care or treatment (pre-ART or ART)
101 who cured on DOTS (Directly Observed Treatment, Short course)
102 No. of hype zoster cases
103 No. of hypertension cases
104 No. of intestinal worms cases
105 No. of malaria blood smear tests
106 No. of malaria cases
107 No. of measles diagnoses
108 No. of measles vaccine
109 No. of meningitis (meningococcal) diagnoses
110 No. of cryptococcal meningitis cases
111 No. of other types of meningitis diagnoses
112 No. of oral diseases and condition cases
113 No. of ORS sachets
114 No. of pap smear tests
115 No. of pelvic inflammatory disease (PID) diagnoses
116 No. of pneumonia cases
117 No. of prurigo cases
118 No. of Quinine
119 No. of referred clients out
120 No. of skin diseases cases
121 No. of STI cases
122 No. of syphilis testing performed
123 No. of syphilis screening tests positive
124 No. of typhoid cases
125 No. of URN (cough) cases
126 No. of UTI cases
127 No. of Widal test positive
128 No. of Widal tests
No. of other drugs, vaccines, contraceptives or supplies that
129 suffered a stock out during the month
No. of pregnant women identified in the community and referred
130 for ANC
131 No. of pregnant women pre test counseled
132 No. of pregnant women referred for PMTCT
133 No. of pregnant women referred and received PMTCT
134 No. of old clients on ANC
135 No. of ANC re-attendance 4th visit
136 No. of new ANC clients
137 No. of clients provided with HBC (Home based care)
138 No. of pregnant women referred out
139 No. of pregnant women tested for HIV
140 No. of pregnant women positive for HIV
141 No. of pregnant and positive mothers under monitoring
No. of pregnant women with known (positive) HIV infection
142 attending ANC for a new pregnancy
No. of pregnant women with known (positive) HIV infection
143 counseled on infant feeding options
No. of pregnant women with known (positive) HIV infection offered
144 septrine prophylaxis
No. of pregnant women with known (positive) HIV infection offered
145 the BCP (ITN's, Condoms, safe water vessel)
146 No. of HIV (+) mothers counseled for FP
147 No. of HIV (+) mothers counseled and received FP
No. of HIV (+) women who received any method of FP post partum
148 period
149 No. of women who received any method of FP post partum
150 No. of HIV (+) mothers screened and tested for STI's
No. of HIV (+) mothers whose partners were screened, tested and
151 treated for STI's
152 No. of partners tested for HIV
153 No. of partners tested positive
154 No. of HIV (+) pregnant women provided with ART
155 No. of ART for HIV (+) pregnant women eligible for treatment
156 No. of HIV (+) pregnant women on HAART (triple therapy)
No. of HIV (+) pregnant women on Prophylactic regimens using a
157 combination of 2 ARVs
No. of HIV (+) pregnant women on Prophylactic regimens using a
158 combination of 3 ARVs
159 No. of HIV (+) pregnant women on Single-dose Nevirapine only
160 No. of HIV (+) women referred and delivered in health care setting
161 No. of live births to HIV (+) mothers
162 No. of deliveries HIV (+) who swallowed ARVs
163 No. of deliveries
No. of HIV (+) mothers initiating exclusive breast feeding within 1
164 hour after delivery
165 No. of HIV (+) exclusively breast feeding mothers
No. of HIV (+) lactating mothers followed up in community for
infant feeding, early infant diagnosis services, or linkage into
166 chronic HIV care
167 No. of HIV (+) non breast feeding mothers
No. of HIV (+) women tested and received results during PNC
168 (new clients)
169 No. of women tested and received results during PNC (new clients)
170 No. of HIV (+) infants born to HIV (+) women who received ART
171 No. of infants born to HIV (+) women given ART prophylaxis (AZT)
No. of infants born to HIV (+) women tested with DNA-PCR and
172 given results
No. of infants born to HIV (+) women tested positive with DNA-
173 PCR and given results
No. of HIV exposed infants given or refilled NVP suspension after
174 6wks of age
175 No. of HIV exposed infants initiated on cotrim prophylaxis
No. of HIV exposed infants initiated on cotrim within 2 months of
176 birth
177 No. of mothers tested for CD4
178 No. of women tested during labor
179 No. of MTC Vulnerable children
180 No. of children referred in
181 No. of children referred out (PIDC, MILDMAY e.t.c.)
182 No. of HIV (+) tested children
183 No. of children under 18 years counseled and tested for HIV
184 No. of children on monitoring (counseling)
185 No. of children on ART
186 No. of dead children
187 No. of deaths
188 No. of discordant couples
189 No. of children immunised for BCG
190 No. of children immunised for DPT- HepB+ Hib 1
191 No. of children immunised for DPT- HepB+ Hib 2
192 No. of children immunised for DPT- HepB+ Hib 3
193 No. of children immunised for Measles
194 No. of children immunised for Polio 0
195 No. of children immunised for Polio 1
196 No. of children immunised for Polio 2
197 No. of children immunised for Polio 3
198 No. of children treated with HOMAPAK
199 No. of children who received HOMAPAK within 24 hours
200 No. of dewormed 1st dose in the year
201 No. of dewormed 2nd dose in the year
202 No. of DPT- HepB+ Hib doses wasted
203 No. of total weighed at measles vaccination
No. of under 5 children who slept under a Net the previous night
204 (as per HOMAPAK)
205 No. of Vit A supplement 1st dose in the year
206 No. of Vit A supplement 2nd dose in the year
207 No. of Vit A supplementation (postnatal)
208 No. of weight below bottom line at Measles vaccination
209 No. of abortions
210 No. of admissions
211 No. of babies born with low birth weight (< 2,5 kg)
212 No. of birth asphyxia
213 No. of deliveries by private practitioners
214 No. of deliveries in unit
215 No. of deliveries with TBA
216 No. of first dose IPT (IPT1)
217 No. of second dose IPT (IPT2)
218 No. of haemorrhage related to pregnancy (aph &/or pph)
219 No. of high blood pressure in pregnancy
220 No. of live births in unit
221 No. of malaria in pregnancy
222 No. of maternal deaths
223 No. of obstructed labour
224 No. of postnatal visits
225 No. of prenatal conditions (in new born 0-28 days)
226 No. of referrals from unit
227 No. of referrals to unit
228 No. of referrals to unit
229 No. of still births in unit
230 No. of non-pregnant women TT vaccine - dose 1
231 No. of non-pregnant women TT vaccine - dose 2
232 No. of non-pregnant women TT vaccine - dose 3
233 No. of non-pregnant women TT vaccine - dose 4
234 No. of non-pregnant women TT vaccine - dose 5
235 No. of pregnant women TT vaccine - dose 1
236 No. of pregnant women TT vaccine - dose 2
237 No. of pregnant women TT vaccine - dose 3
238 No. of pregnant women TT vaccine - dose 4
239 No. of pregnant women TT vaccine - dose 5
240 Lab has capacity
241 No. of new attendance
242 No. of re-attendance
243 No. of referrals from unit (all ages)
244 No. of referrals to unit (all ages)
245 No. of total attendance
246 No. of deaths in OPD
247 No. of acute flaccid paralysis diagnoses
248 No. of cholera diagnoses
249 No. of guinea worm diagnoses
250 No. of other emerging infectious disease (specify) diagnoses
251 No. of other viral haemorrhagic fevers diagnoses
252 No. of plaque diagnoses
253 No. of rabies diagnoses
254 No. of tetanus (neonatal)(0-28 days age) diagnoses
255 No. of yellow fever diagnoses
256 No. of leprosy diagnoses
257 No. of no pneumonia - cough or cold diagnoses
258 No. of onchocerciasis diagnoses
259 No. of schistosomiasis diagnoses
260 No. of sleeping sickness diagnoses
261 No. of tetanus (over 28 days age) diagnoses
262 No. of alcohol and drug abuse diagnoses
263 No. of animal/snakes bites diagnoses
264 No. of childhood mental disorders diagnoses
265 No. of diabetes mellitus diagnoses
266 No. of epilepsy diagnoses
267 No. of gastro-intestinal disorders (non-infective) diagnoses
268 No. of injuries- road traffic accidents diagnoses
269 No. of injuries= (trauma due to other causes)- diagnoses
-70 No. of low wpinht for an riannne
271 No. of other cardiovascular diseases diagnoses
272 No. of anxiety disorders diagnoses
273 No. of mania diagnoses
274 No. of schizophrenia diagnoses
275 No. of other forms of mental illness diagnoses
No. of severe malnutrition (marasmus, kwashiorkor and marasmic-
276 kwash) diagnoses
277 No. of other diagnoses (priority diseases for district)
278 No. of all others diagnoses
279 No. of total diagnoses
280 No. of other lab. tests
Appendix I - List of Conducted Interviews
Dorothy Kibirige, Monitoring
and Evaluation Program
Manager
Kyetume Community Based Health
Care Programme
In-Person Interview.
March 2011; Kyetume,
Uganda.
Henry Titus Kayondo, Gender Kyetume Community Based Health In-Person Interview.
Based Violence Program Care Programme March 2011; Kyetume,
Manager Uganda.
Lara Gomez, Research PACT Project, Harvard School of Public In-Person Interview.
Manager of HIV Services Health and Partners in Health, March 2011;
Brigham Women's Hospital Cambridge, MA
Matthew Peckarsky, Manager Partners in Health Phone Interview.
of Health Surveillance and March 2011
Evaluation
Brenda Rose, Housing AIDS Action Committee, Boston Phone Interview.
Advocacy February 2011
Bernard Kakuhikire, Program Sustainable Household Income Project In-Person Interview.
Director February 2011;
Cambridge, MA
Veronica Miller, Executive Forum for Collaborative HIV Research Phone Interview.
Director March 2011
Eric Brus, Health Library AIDS Action Committee, Boston Phone Interview.
March 2011
Erin Sullivan MIT Sloan School of Management, In-Person Interview.
Partners in Health February 2011
Mark Damesyn, Research California Department of Public Email Correspondence
Health, Office of AIDS February 2011
Pamela Ogata, Research and Los Angeles Office of AIDS Programs Phone Interview.
Evaluation and Policy February 2011
